RayKnowChina Research Map
Shortlist

HarbinHarbin Medical University

Harbin Medical University Cancer Hospital

哈尔滨医科大学附属肿瘤医院

Listed for 14 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Harbin Medical University Cancer Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌0 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌12 papers led
  3. Hepatocellular carcinoma肝细胞癌58 papers led
  4. Stomach cancer胃癌66 papers led
  5. Lung cancer肺癌156 papers led
  6. Pancreatic cancer胰腺癌27 papers led
  7. Breast cancer乳腺癌168 papers led1 open trial led
  8. Glioma胶质瘤14 papers led
  9. Osteosarcoma骨肉瘤2 papers led
  10. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  11. Multiple myeloma多发性骨髓瘤6 papers led
  12. Lymphoma淋巴瘤26 papers led
  13. Fanconi anaemia范可尼贫血0 papers led
  14. IgA nephropathyIgA 肾病0 papers led

Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Neuroblastoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Coronary heart disease, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led no English-language PubMed papers on nasopharyngeal carcinoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Harbin for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 12 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
12
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 4420212022: 1120222023: 1120232024: 4420242025: 112025

1 hospital in Harbin for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07700667

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Shiyan, Taiyuan, Tianjin, Xi'an, Zhengzhou

  2. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

  3. Not yet recruiting
    A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07623642

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapyNeoadjuvant & combined treatmentMolecular markers & genomics
Departments in papersMedical oncologyRadiation oncologyRadiology / nuclear medicinePathology / laboratory medicine
Papers it led12
  1. Intratumoral and peritumoral heterogeneity based on CT to predict the pathological response after neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.2026International journal of surgery (London, England)Free full text
  2. Preoperative conversion therapy of camrelizumab combined with paclitaxel and nedaplatin for unresectable advanced esophageal squamous cell carcinoma: a phase 2 study.2025BMC medicineFree full text
  3. Analysis of multiple programmed cell death-related prognostic genes and functional validations of necroptosis-associated genes in oesophageal squamous cell carcinoma.2024EBioMedicineFree full text
  4. Nucleoporin 93, a new substrate of the E3 ubiquitin protein ligase HECTD1, promotes esophageal squamous cell carcinoma progression.2024Human cell
  5. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).2024International journal of surgery (London, England)Free full text
  6. Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.2024Journal of translational medicineFree full text
  7. Response to neoadjuvant immune checkpoint inhibitors and chemotherapy in Chinese patients with esophageal squamous cell carcinoma: the role of tumor immune microenvironment.2023Cancer immunology, immunotherapy : CIIFree full text
  8. Identification and validation of an eight-lncRNA signature that predicts prognosis in patients with esophageal squamous cell carcinoma.2022Cellular & molecular biology lettersFree full text
  9. Photodynamic therapy induces human esophageal carcinoma cell pyroptosis by targeting the PKM2/caspase-8/caspase-3/GSDME axis.2021Cancer letters
  10. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling.2021Cell cycle (Georgetown, Tex.)Free full text
  11. Dihydroartemisinin mediating PKM2-caspase-8/3-GSDME axis for pyroptosis in esophageal squamous cell carcinoma.2021Chemico-biological interactions
  12. UBE2T Contributes to the Prognosis of Esophageal Squamous Cell Carcinoma.2021Pathology oncology research : PORFree full text
All its trials on ClinicalTrials.gov, any status19
  1. Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaActive, not recruitingNCT07682376Lead (inferred)Phase 2Start 2026-06
  2. A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.Not yet recruitingNCT07623642Study sitePhase 2Start 2026-06
  3. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  4. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  5. A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT06512428Study sitePhase 2Start 2024-03
  6. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11
  7. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  8. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  9. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  10. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedNCT04949256Study sitePhase 3Start 2021-07
  11. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
  12. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaCompletedNCT03957590Study sitePhase 3Start 2019-06
  13. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01
  14. Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT03817567Study sitePhase 1/Phase 2Start 2018-07
  15. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
  16. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CarcinomaCompletedNCT03469557Study sitePhase 2Start 2017-07
  17. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyCompletedNCT03933449Study sitePhase 3Start 2016-12
  18. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  19. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Study sitePhase 3Start 2015-11
More papers found outside PubMed (not counted)32
  1. 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  2. 272. CAMRELIZUMAB, PACLITAXEL AND NEDAPLATIN AS CONVERSION THERAPY FOR LOCALLY ADVANCED/ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II, SINGLE-ARM STUDY2025Diseases of the Esophagusarticle
  3. 287. CAMRELIZUMAB, PACLITAXEL AND NEDAPLATIN AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESPRIT): A PHASE II, SINGLE-ARM STUDY2025Diseases of the Esophagusarticle
  4. 305P Safety and efficacy of endoscopic resection followed by adjuvant chemoradiotherapy (ERACT) for organ preservation in early-stage oesophageal squamous cell carcinoma with high-risk features: A prospective, multicenter, phase II clinical2025Annals of Oncologyarticle
  5. 349. PATHOLOGIC COMPLETE RESPONSE IN ESOPHAGEAL SQUAMOUS CELL CANCER: DO DIVERSE NEOADJUVANT MODALITIES PREDICT PROGNOSTIC DIFFERENCES?2025Diseases of the Esophagusarticle
  6. Camrelizumab combined with paclitaxel and nedaplatin as conversion therapy for locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm exploratory study.2025Journal of Clinical Oncologyarticle
  7. Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase II, single-arm, exploratory research.2025Journal of Clinical Oncologyarticle
  8. LBA79 Lenvatinib plus pembrolizumab and chemotherapy vs pembrolizumab and chemotherapy in untreated metastatic esophageal squamous cell carcinoma: The randomized phase III LEAP-014 study2025Annals of Oncologyconference-abstract
  9. Perioperative adebrelimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: A single-arm, open-label, multicenter study.2025Journal of Clinical Oncologyconference-abstract
  10. Tumor Microenvironment-Guided Fine-Tuning of Pathology Foundation Models for Esophageal Squamous Cell Carcinoma Immunotherapy Response Prediction2025Lecture notes in computer scienceconference-paper
  11. 187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies2024Annals of Oncologyarticle
  12. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncologyconference-abstract
  13. 189P Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)2023Annals of Oncologyarticle
  14. Abstract CT076: Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis2023Cancer Researchconference-abstract
  15. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  16. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  17. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  18. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  19. Development and validation of a survival prediction model for patients with esophageal squamous cell carcinoma of the thoracic segment with pT1-2 lymph node metastasis2023Research Squarepreprint
  20. Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).2023Journal of Clinical Oncologyconference-abstract
  21. O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)2023Annals of Oncologyarticle
  22. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncologyarticle
  23. 155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm pha2021Annals of Oncologyarticle
  24. 65P Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase II, single-arm, exploratory research2021Annals of Oncologyarticle
  25. 66P Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm, exploratory research2021Annals of Oncologyarticle
  26. CS1001-304: A phase III study of fluorouracil and cisplatin (FP) with CS1001, an anti-PD-L1 antibody, or placebo in unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract
  27. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract
  28. Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract
  29. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncologyconference-abstract
  30. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Squarepreprint
  31. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Squarepreprint
  32. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 58 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
58
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
13
led by another institution
Papers led per year
2021: 7720212022: 121220222023: 151520232024: 101020242025: 11112025

4 hospitals in Harbin for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 13

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    First in Human Study of SIM0610 in Solid Tumors
    Phase
    Phase 1
    Started
    2026-01
    Posted
    Registry
    NCT07348211

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChongqing, Harbin, Shanghai, Shenyang

  2. Recruiting
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07547553

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Zhengzhou

  3. Recruiting
    Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
    Phase
    Phase 2/Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06796803

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 1 listed hospital as study siteHarbin, Shanghai

  4. Recruiting
    JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06954467

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou

  5. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Posted
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  6. Recruiting
    NWRD06 DNA Plasmid for HCC After Curative Resection.
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07324304

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Harbin

  7. Recruiting
    Phase 2 Study of WGI-0301 for Advanced HCC
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06309485

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan

  8. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  9. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Posted
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai

  10. Not yet recruiting
    The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
    Phase
    Not given
    Started
    2026-07
    Posted
    Registry
    NCT07724951

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 6 listed hospitals as study sitesGuangzhou, Harbin, Nanning, Qingdao, Shanghai

  11. Not yet recruiting
    Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07761286

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHarbin

  12. Not yet recruiting
    JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07823348

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shanghai

  13. Not yet recruiting
    Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
    Phase
    N/A
    Started
    2025-06
    Posted
    Registry
    NCT07010588

    Age 18 years to 75 years (registered criteria)

    Led by Peking University People's Hospital; 8 listed hospitals as study sitesBeijing, Changchun, Chongqing, Harbin, Jinan, Qingdao, Wuhan, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging, AI & early detectionRecurrence & prognosisImmunotherapy & targeted drugs
Departments in papersRadiology / nuclear medicineMedical oncologySurgery (general/hepatobiliary/pancreatic)Radiation oncology
Papers it led58
  1. In Situ Assembly of Transformable Monopeptide on Activated Neutrophils Attenuates NETs-Induced Hepatocellular Carcinoma Metastasis by Disrupting NE Nuclear Translocation.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Integrating lesser omentum adipose CT in dual-phase tumor imaging: A multi-label deep learning framework for preoperative microvascular invasion prediction and survival analysis in hepatocellular carcinoma.2026Computer methods and programs in biomedicine
  3. An etiology-stratified single-cell atlas identifies FABP4 as a prognostic marker for MASLD-related HCC.2026Journal of hepatology
  4. Deep Learning-Based Prediction of Microvascular Invasion and Survival Outcomes in Hepatocellular Carcinoma Using Dual-phase CT Imaging of Tumors and Lesser Omental Adipose: A Multicenter Study.2025Academic radiology
  5. Targeted nanosensitizer-augmented sono-immunotherapy with STING agonist to remodel the immune microenvironment in hepatocellular carcinoma.2025Acta biomaterialia
  6. Deep learning-based CT radiomics predicts prognosis of unresectable hepatocellular carcinoma treated with TACE-HAIC combined with PD-1 inhibitors and tyrosine kinase inhibitors.2025BMC gastroenterologyFree full text
  7. Targeting RECQL4 in hepatocellular carcinoma: from prognosis to therapeutic potential.2025BMC medical genomicsFree full text
  8. TAPP@NBs combined with GSNO to enhance the anti-liver cancer effect of sonodynamic therapy.2025Biomedical materials (Bristol, England)
  9. Comparing neoadjuvant targeted therapy plus transarterial chemoembolization versus triple therapy including immunotherapy in hepatocellular carcinoma: a Chinese multicentre study.2025Cancer immunology, immunotherapy : CIIFree full text
  10. Comparative analysis of metabolome and transcriptomes to explore the inhibited influence of sonodynamic therapy combined with lonidamine on hepatocellular carcinoma.2025Drug deliveryFree full text
  11. The transcription factor HOXB7 significantly enhances the expression of PIGT through the Wnt/β-catenin signaling pathway, thereby promoting the proliferation and deterioration of HCC.2025Expert review of anticancer therapy
  12. TACE-HAlC combined with Donafenib and immune checkpoint inhibitors for BCLC stage C HCC patients (THEME study): a retrospective IPTW-adjusted cohort study.2025Frontiers in immunologyFree full text
  13. Macrophage hitchhiking for systematic suppression in postablative multifocal HCC.2025Hepatology (Baltimore, Md.)
  14. Ultrasound-responsive nanobubble-mediated sonodynamic therapy sensitizes disulfidptosis in the treatment of liver hepatocellular carcinoma.2025Ultrasonics sonochemistryFree full text
  15. NIR-II Light-Actuated Nanomotors for Enhanced Photoimmunotherapy Toward Hepatocellular Carcinoma.2024ACS applied materials & interfaces
  16. Reply to the Letter from Qian Ren and Yanjun Wang About the Article, "LI-RADS Morphological Type Predicts Prognosis of Patients with Hepatocellular Carcinoma After Radical Resection".2024Annals of surgical oncology
  17. Three-dimensional morphology scoring of hepatocellular carcinoma stratifies prognosis and immune infiltration.2024Computers in biology and medicine
  18. SHR6390 Combined with Cabozantinib Inhibits Tumor Progression in the Hepatocellular Carcinoma Mouse Model.2024Current gene therapy
  19. CsxWO3@NBs as a Multi-Image Guided Photothermal/Photodynamic Combination Therapy Platform for the Treatment of Hepatocellular Carcinoma.2024International journal of nanomedicineFree full text
  20. Integrated single-cell transcriptome and TCR profiles of hepatocellular carcinoma highlight the convergence on interferon signaling during immunotherapy.2024Journal for immunotherapy of cancerFree full text
  21. The mechanism and experimental verification of Ixeris sonchifolia promoting apoptosis of hepatocellular carcinoma based on network pharmacology: Ixeris sonchifolia Induces Hepatocellular Carcinoma Apoptosis via the PI3K/AKT Pathway.2024Journal of ethnopharmacology
  22. Synergistic SDT/cuproptosis therapy for liver hepatocellular carcinoma: enhanced antitumor efficacy and specific mechanisms.2024Journal of nanobiotechnologyFree full text
  23. Clinical prediction of microvascular invasion in hepatocellular carcinoma using an MRI-based graph convolutional network model integrated with nomogram.2024The British journal of radiologyFree full text
  24. Prognostic factors in patients with first diagnosis of hepatocellular carcinoma presenting with pulmonary metastasis and construction of a clinical prediction model.2024Updates in surgery
  25. LI-RADS Morphological Type Predicts Prognosis of Patients with Hepatocellular Carcinoma After Radical Resection.2023Annals of surgical oncology
  26. Pan-cancer analysis of SYNGR2 with a focus on clinical implications and immune landscape in liver hepatocellular carcinoma.2023BMC bioinformaticsFree full text
  27. Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors.2023BMC cancerFree full text
  28. BTF3 promotes proliferation and glycolysis in hepatocellular carcinoma by regulating GLUT1.2023Cancer biology & therapyFree full text
  29. A radiomics signature associated with underlying gene expression pattern for the prediction of prognosis and treatment response in hepatocellular carcinoma.2023European journal of radiology
  30. Interleukin-35 expression promotes hepatocellular carcinogenesis by inducing γδ T-cell exhaustion.2023Genomics
  31. The combination of circulating IgM and geriatric nutritional risk index predicts the prognostic of hepatocellular carcinoma patients who underwent immune checkpoint inhibitors.2023International immunopharmacology
  32. Recent advances in natural polysaccharides against hepatocellular carcinoma: A review.2023International journal of biological macromolecules
  33. Sonosensitizer Nanoplatforms Augmented Sonodynamic Therapy-Sensitizing Shikonin-Induced Necroptosis Against Hepatocellular Carcinoma.2023International journal of nanomedicineFree full text
  34. IR-820@NBs Combined with MG-132 Enhances the Anti-Hepatocellular Carcinoma Effect of Sonodynamic Therapy.2023International journal of nanomedicineFree full text
  35. Sono-Immunotherapy Mediated Controllable Composite Nano Fluorescent Probes Reprogram the Immune Microenvironment of Hepatocellular Carcinoma.2023International journal of nanomedicineFree full text
  36. Establishment and Validation of the LI-RADS Morphologic Type II Hepatocellular Carcinoma Early Recurrence Risk Scoring System.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  37. ZMIZ1 Upregulation of TET3-Mediated Hydroxymethylation Induces M2 Polarization of Kupffer Cells in Hepatocellular Carcinogenesis by Mediating Notch1/c-Myc Signaling.2023Laboratory investigation; a journal of technical methods and pathology
  38. Circ_RBM23 knockdown suppresses chemoresistance, proliferation, migration and invasion of sorafenib-resistant HCC cells through miR-338-3p/RAB1B axis.2023Pathology, research and practice
  39. Clinical value of combined preoperative-postoperative neutrophil-to-lymphocyte ratio in predicting hepatocellular carcinoma prognosis after radiofrequency ablation.2023The British journal of radiologyFree full text
  40. Pharmacokinetic analysis of different contrast agents on multiphase enhanced MRI for microvascular invasion: preoperative prediction in hepatocellular carcinoma.2022Acta radiologica (Stockholm, Sweden : 1987)
  41. Preoperative PDW levels predict pulmonary metastasis in patients with hepatocellular carcinoma.2022BMC cancerFree full text
  42. Utility of mean platelet volume in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.2022BMC gastroenterologyFree full text
  43. Lean body mass predicts postoperative liver failure in patients with hepatocellular carcinoma.2022Cancer biomarkers : section A of Disease markersFree full text
  44. Dose of intra-operative opioids has no impact on recurrence or survival in primary liver cancer.2022Cancer medicineFree full text
  45. A Ferroptosis-Related LncRNA Signature Associated with Prognosis, Tumor Immune Environment, and Genome Instability in Hepatocellular Carcinoma.2022Computational and mathematical methods in medicineRCTFree full text
  46. Development and validation of four ferroptosis-related gene signatures and their correlations with immune implication in hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  47. A phase I pharmacokinetic study of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma.2022Future oncology (London, England)
  48. RNA-Seq Explores the Mechanism of Oxygen-Boosted Sonodynamic Therapy Based on All-in-One Nanobubbles to Enhance Ferroptosis for the Treatment of HCC.2022International journal of nanomedicineFree full text
  49. Comparison of 8spheres polyvinyl alcohol microsphere and gelatin sponge particle efficacy for transcatheter arterial chemoembolization in stages A to B patients with hepatocellular carcinoma.2022Journal of cancer research and therapeutics
  50. Dynamic Contrast-Enhanced Ultrasonography with Sonazoid for Diagnosis of Microvascular Invasion in Hepatocellular Carcinoma.2022Ultrasound in medicine & biology
  51. Prediction Model and Nomogram of Early Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation Based on Logistic Regression Analysis.2022Ultrasound in medicine & biology
  52. Value of gadoxetic acid-enhanced MRI for microvascular invasion of small hepatocellular carcinoma: a retrospective study.2021BMC medical imagingFree full text
  53. Circ_0004018 suppresses cell proliferation and migration in hepatocellular carcinoma via miR-1197/PTEN/PI3K/AKT signaling pathway.2021Cell cycle (Georgetown, Tex.)Free full text
  54. Enhanced expression of miR-889 forecasts an unfavorable prognosis and facilitates cell progression in hepatocellular carcinoma.2021Diagnostic pathologyFree full text
  55. Synergistic Anticancer Strategy of Sonodynamic Therapy Combined with PI-103 Against Hepatocellular Carcinoma.2021Drug design, development and therapyFree full text
  56. Novel small molecule inhibitors of the transcription factor ETS-1 and their antitumor activity against hepatocellular carcinoma.2021European journal of pharmacology
  57. Oxygen-sufficient lipid nanobubbles combined with UTMD for enhanced sonodynamic therapy of Hep-G2 cells.2021Journal of biomedical materials research. Part B, Applied biomaterials
  58. Single-cell RNA sequencing reveals the mechanism of sonodynamic therapy combined with a RAS inhibitor in the setting of hepatocellular carcinoma.2021Journal of nanobiotechnologyFree full text
All its trials on ClinicalTrials.gov, any status36
  1. Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular CarcinomaNot yet recruitingNCT07761286Study sitePhase 1/Phase 2Start 2026-09
  2. First in Human Study of SIM0610 in Solid TumorsRecruitingNCT07348211Study sitePhase 1Start 2026-01
  3. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Study sitePhase 1/Phase 2Start 2026-05
  4. The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical StudyNot yet recruitingNCT07724951Study siteStart 2026-07
  5. JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver CancerNot yet recruitingNCT07823348Study sitePhase 3Start 2026-10
  6. NWRD06 DNA Plasmid for HCC After Curative Resection.RecruitingNCT07324304Study sitePhase 2Start 2025-12
  7. Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)RecruitingNCT06796803Study sitePhase 2/Phase 3Start 2025-02
  8. JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06954467Study sitePhase 2Start 2025-05
  9. Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High RiskNot yet recruitingNCT07010588Study siteN/AStart 2025-06
  10. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  11. Phase 2 Study of WGI-0301 for Advanced HCCRecruitingNCT06309485Study sitePhase 2Start 2024-07
  12. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  13. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Study sitePhase 1/Phase 2Start 2021-11
  14. A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)TerminatedNCT06487559Study sitePhase 1Start 2024-09
  15. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Active, not recruitingNCT05904886Study sitePhase 3Start 2023-09
  16. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Study sitePhase 3Start 2021-03
  17. Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04741165Study sitePhase 2Start 2021-01
  18. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCCCompletedNCT04948697Study sitePhase 2Start 2021-08
  19. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Study sitePhase 3Start 2020-05
  20. The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular CarcinomaCompletedNCT04542837Study sitePhase 2Start 2020-09
  21. Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular CarcinomaCompletedNCT04401800Study sitePhase 2Start 2020-09
  22. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  23. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  24. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12
  25. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12
  26. A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular CarcinomaCompletedNCT04194801Study sitePhase 1/Phase 2Start 2019-12
  27. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  28. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Study sitePhase 3Start 2018-12
  29. Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Study sitePhase 2Start 2018-04
  30. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular CarcinomaCompletedNCT03434379Study sitePhase 3Start 2018-03
  31. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Study sitePhase 3Start 2017-04
  32. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  33. A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCCCompletedNCT03516071Study sitePhase 2Start 2017-05
  34. Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT02953743Study sitePhase 1Start 2016-09
  35. A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaCompletedNCT02508467Study sitePhase 1Start 2015-07
  36. Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular CarcinomaCompletedNCT01988493Study sitePhase 1/Phase 2Start 2014-01

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 66 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.7%.

Papers led
66
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
16
led by another institution
Papers led per year
2021: 151520212022: 6620222023: 7720232024: 171720242025: 20202025

4 hospitals in Harbin for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 16

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  2. Recruiting
    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
    Phase
    Phase 3
    Started
    2025-05
    Posted
    Registry
    NCT06901531

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Shanghai, Shijiazhuang, Tianjin, Wuhan, Xining, Zhengzhou

  3. Recruiting
    A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07023315

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Harbin, Shanghai, Shijiazhuang

  4. Recruiting
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07066657

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Shanghai, Wuhan, Zhengzhou

  5. Recruiting
    Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07102901

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Zhengzhou

  6. Recruiting
    Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07127822

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Harbin, Qingdao, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  7. Recruiting
    DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
    Phase
    Phase 2/Phase 3
    Started
    2024-02
    Posted
    Registry
    NCT06221748

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Harbin, Jinan, Kunming, Qingdao, Shanghai, Wuhan, Xiamen, Xuzhou, Zhengzhou

  8. Recruiting
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    Phase
    Phase 1/Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06324357

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou

  9. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  10. Recruiting
    To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
    Phase
    Phase 2/Phase 3
    Started
    2024-08
    Posted
    Registry
    NCT06504732

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shenyang

  11. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Posted
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xining, Xuzhou, Yinchuan, Zhengzhou

  12. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  13. Recruiting
    A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-12
    Posted
    Registry
    NCT06783569

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shenyang

  14. Recruiting
    Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2023-04
    Posted
    Registry
    NCT05918094

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 7 listed hospitals as study sitesChengdu, Dalian, Guangzhou, Harbin, Nanchang, Shanghai, Wuhan, Zhengzhou

  15. Recruiting
    Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06155383

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Jinan, Kunming, Xiamen, Zhengzhou

  16. Recruiting
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2021-06
    Posted
    Registry
    NCT04900818

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AISurgeryPeritoneal spread & advanced disease
Departments in papersGastroenterology / hepatologyMedical oncologyRadiology / nuclear medicinePathology / laboratory medicine
Papers it led66
  1. Noninvasive detection and differentiation of gastric malignancy using cell-free DNA biomarkers.2026Journal of advanced researchFree full text
  2. Effect of sevoflurane-based or propofol-based anesthesia on acute kidney injury after surgery for gastric cancer: a retrospective propensity score-matched analysis.2025BMC anesthesiologyFree full text
  3. Predictive value of 18F-FDG PET/CT metabolic parameters for gastric cancer patients' microsatellite instability status.2025BMC cancerFree full text
  4. The prealbumin-CD19+ index predicts surgical survival in patients with GC.2025BMC cancerFree full text
  5. Sedated and unsedated gastroscopy has no influence on the outcomes of patients with gastric cancer: a retrospective study.2025BMC cancerFree full text
  6. Enhanced recovery after gastrectomy: updated Meta-analysis of 27 randomized trials (2018-2025).2025BMC surgeryFree full text
  7. A Comprehensive Analysis of the Clinical Significance and Underlying Oncogenic Roles of Specific MMPs in Gastric Carcinoma Reveals their Potential Roles in Prognosis and Therapy.2025Current molecular medicineFree full text
  8. Skeletal muscle index combined with IgM predicts prognosis in gastric cancer patients who underwent surgery.2025Frontiers in immunologyFree full text
  9. Treatment patterns and outcomes in advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in China.2025Future oncology (London, England)Free full text
  10. Comparison of Short-Term Outcomes of Robot-Assisted Distal Gastrectomy Using the KangDuo Surgical Robot-01 System and Laparoscopic Gastrectomy.2025Journal of laparoendoscopic & advanced surgical techniques. Part A
  11. Study on the Safety and Effectiveness of Using Modified Tubular Stomach for Sideoverlap Anastomosis in Laparoscopic Proximal Gastrectomy.2025Journal of laparoendoscopic & advanced surgical techniques. Part A
  12. Effects of enhanced recovery after surgery nursing combined with early enteral nutrition on Gastrointestinal function recovery after radical gastrectomy.2025Langenbeck's archives of surgeryRCTFree full text
  13. A Polysaccharide-Based Fluorescent Polymer Carrier for Natural Product Delivery and Gastric Cancer Inhibition.2025Luminescence : the journal of biological and chemical luminescence
  14. Metabolic and aging related gene risk score for therapeutic stratification and precision oncology in gastric cancer.2025MedicineFree full text
  15. Nutritional Risk Index (NRI) predicts the clinical outcomes of patients with gastric cancer who received immune checkpoint inhibitors (PD-1/PD-L1).2025MedicineFree full text
  16. A large histological images dataset of gastric cancer with tumour microenvironment annotation for AI.2025Scientific dataFree full text
  17. LRP12 promotes gastric cancer progression through AKT/mTOR signaling and M2 macrophage-mediated immunosuppression.2025Scientific reportsFree full text
  18. Integrating psychological and dietary care for patients with advanced gastric cancer undergoing chemotherapy: a randomized controlled trial.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCT
  19. Clinical application of the KangDuo-Surgical Robot-01 in distal gastrectomy for gastric cancer.2025Updates in surgery
  20. Pescadillo ribosomal biogenesis factor 1 and programmed death-ligand 1 in gastric and head and neck squamous cell carcinoma.2025World journal of gastroenterologyFree full text
  21. Machine learning-based reconstruction of prognostic staging for gastric cancer patients with different differentiation grades: A multicenter retrospective study.2025World journal of gastroenterologyFree full text
  22. Integrin β5, a noninvasive diagnostic biomarker, is associated with unfavorable prognosis and immunotherapy efficacy in gastric cancer.2024BMC gastroenterologyFree full text
  23. Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor.2024Cancer medicineFree full text
  24. EIF2S2 transcriptionally upregulates HIF1α to promote gastric cancer progression via activating PI3K/AKT/mTOR pathway.2024Carcinogenesis
  25. A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer.2024Current gene therapy
  26. Preoperative glucose-to-lymphocyte ratio predicts survival in cancer.2024Frontiers in endocrinologyFree full text
  27. Eco-friendly green synthesis of N‑pyrazole amino chitosan using PEG-400 as an anticancer agent against gastric cancer cells via inhibiting EGFR.2024In vitro cellular & developmental biology. Animal
  28. Normalization weighted combination scores re-evaluate TNM staging of gastric cancer: a retrospective cohort study based on a multicenter database.2024International journal of surgery (London, England)Free full text
  29. Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer.2024Investigational new drugsFree full text
  30. CD3+/CD4+ cells combined with myosteatosis predict the prognosis in patients who underwent gastric cancer surgery.2024Journal of cachexia, sarcopenia and muscleFree full text
  31. Pan-cancer analysis of SERPINE1 with a concentration on immune therapeutic and prognostic in gastric cancer.2024Journal of cellular and molecular medicineFree full text
  32. Overall survival prediction of gastric cancer using the gene signature of CT-detected extramural venous invasion combined with M2 macrophages infiltration.2024Journal of translational medicineFree full text
  33. Geriatric nutritional risk index predicts the prognosis of gastric cancer patients treated with immune checkpoint inhibitors.2024MedicineFree full text
  34. EIF4A3-induced circle RNA_ 0001860 promotes growth, invasion, and immune evasion of gastric cancer cells through the miR-618/HMGA2 axis.2024Neoplasma
  35. Prediction of surgical benefit in gastric cancer patients with peritoneal metastasis treated with hyperthermic intraperitoneal chemotherapy.2024Updates in surgeryFree full text
  36. Machine learning algorithms able to predict the prognosis of gastric cancer patients treated with immune checkpoint inhibitors.2024World journal of gastroenterologyFree full text
  37. Development and validation of a prognostic immunoinflammatory index for patients with gastric cancer.2024World journal of gastroenterologyFree full text
  38. Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor.2024World journal of gastroenterologyFree full text
  39. Letter to the editor on"Prognostic significance of preoperative tumor markers combined with controlling nutritional status score in gastric cancer".2023Asian journal of surgery
  40. Development and Validation of Tumor Marker Indices in Advanced Gastric Cancer Patients.2023Cancer control : journal of the Moffitt Cancer CenterFree full text
  41. Prognostic importance of the preoperative New-Naples prognostic score for patients with gastric cancer.2023Cancer medicineFree full text
  42. Prediction model based on radiomics and clinical features for preoperative lymphovascular invasion in gastric cancer patients.2023Future oncology (London, England)
  43. A new nomogram for assessing complete response (CR) in gastric diffuse large B-cell lymphoma (DLBCL) patients after chemotherapy.2023Journal of cancer research and clinical oncologyFree full text
  44. The prognostic marker elastin correlates with epithelial-mesenchymal transition and vimentin-positive fibroblasts in gastric cancer.2023The journal of pathology. Clinical researchFree full text
  45. Cancer-associated fibroblast expression of glutamine fructose-6-phosphate aminotransferase 2 (GFPT2) is a prognostic marker in gastric cancer.2023The journal of pathology. Clinical researchFree full text
  46. Impact of AADAC gene expression on prognosis in patients with Borrmann type III advanced gastric cancer.2022BMC cancerFree full text
  47. The Survival Relationship between Preoperative Inflammation Markers and Patients with Special Pathological Types of Gastric Cancer.2022Canadian journal of gastroenterology & hepatologyFree full text
  48. FSIP1 Is Associated with Poor Prognosis and Can Be Used to Construct a Prognostic Model in Gastric Cancer.2022Disease markersFree full text
  49. Evaluation of Immune Infiltration Based on Image Plus Helps Predict the Prognosis of Stage III Gastric Cancer Patients with Significantly Different Outcomes in Northeastern China.2022Disease markersFree full text
  50. Development and validation of a necroptosis-related gene prognostic score to predict prognosis and efficiency of immunotherapy in gastric cancer.2022Frontiers in immunologyFree full text
  51. Laparoscopic versus open gastrectomy for gastric cancer: A systematic review and meta-analysis of randomized controlled trials.2022International journal of surgery (London, England)
  52. Development and validation of an individual alternative splicing prognostic signature in gastric cancer.2021AgingFree full text
  53. The landscape of alternative splicing reveals novel events associated with tumorigenesis and the immune microenvironment in gastric cancer.2021AgingFree full text
  54. Proximal gastrectomy with gastric tube reconstruction or jejunal interposition reconstruction in upper-third gastric cancer: which offers better short-term surgical outcomes?2021BMC surgeryFree full text
  55. Preoperative Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Stage I-III Gastric Cancer Patients with a MGC Component.2021BioMed research internationalFree full text
  56. The Ratio of the Hemoglobin to Red Cell Distribution Width Combined with the Ratio of Platelets to Lymphocytes Can Predict the Survival of Patients with Gastric Cancer Liver Metastasis.2021BioMed research internationalFree full text
  57. Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine.2021Cancer chemotherapy and pharmacology
  58. Prognostic significance of serum inflammation indexes in different Lauren classification of gastric cancer.2021Cancer medicineFree full text
  59. ELF3-AS1 contributes to gastric cancer progression by binding to hnRNPK and induces thrombocytosis in peripheral blood.2021Cancer scienceFree full text
  60. Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer.2021Frontiers in immunologyFree full text
  61. Comprehensive Characterization of RNA Processing Factors in Gastric Cancer Identifies a Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses.2021Frontiers in immunologyFree full text
  62. Serum CD4 Is Associated with the Infiltration of CD4+T Cells in the Tumor Microenvironment of Gastric Cancer.2021Journal of immunology researchFree full text
  63. A novel long noncoding RNA, TMEM92-AS1, promotes gastric cancer progression by binding to YBX1 to mediate CCL5.2021Molecular oncologyFree full text
  64. In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator.2021Pathology oncology research : PORFree full text
  65. eEF2K as a novel metastatic and prognostic biomarker in gastric cancer patients.2021Pathology, research and practice
  66. Application value of hand-sewn anastomosis in totally laparoscopic total gastrectomy for gastric cancer.2021World journal of surgical oncologyFree full text
Chinese-language papers (not in the count)1
  1. [Exploration of gasless laparoscopic gastric cancer surgery].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status53
  1. A Clinical Study for Comparison of the Effects Between Gasless Laparoscopy and Conventional Laparoscopy for Distal Gastric CancerStatus unknownNCT05495217Lead (inferred)N/AStart 2021-12
  2. Nonintervention Study on Peritoneal Metastasis of Stage IV Gastric CancerStatus unknownNCT03237507Lead (inferred)Start 2017-07
  3. Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric CancerTerminatedNCT01665274Lead (inferred)Phase 2Start 2013-09
  4. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  5. Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction AdenocarcinomaRecruitingNCT07102901Study sitePhase 2Start 2025-09
  6. A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruitingNCT06901531Study sitePhase 3Start 2025-05
  7. A Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsRecruitingNCT07066657Study sitePhase 1Start 2025-07
  8. Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric CancerRecruitingNCT07127822Study sitePhase 2Start 2025-12
  9. A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ AdenocarcinomaRecruitingNCT07023315Study sitePhase 3Start 2025-08
  10. A Phase 2 Clinical Study of ABSK061 and ABSK043RecruitingNCT06632262Study sitePhase 2Start 2024-11
  11. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  12. A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid TumorsRecruitingNCT06783569Study sitePhase 1Start 2024-12
  13. DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyRecruitingNCT06221748Study sitePhase 2/Phase 3Start 2024-02
  14. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingNCT06324357Study sitePhase 1/Phase 2Start 2024-06
  15. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  16. To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric CancerRecruitingNCT06504732Study sitePhase 2/Phase 3Start 2024-08
  17. Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT06155383Study sitePhase 2Start 2023-11
  18. Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT05918094Study sitePhase 3Start 2023-04
  19. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsRecruitingNCT04900818Study sitePhase 1Start 2021-06
  20. Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active, not recruitingNCT06710132Study sitePhase 1/Phase 2Start 2025-01
  21. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Study sitePhase 3Start 2024-05
  22. A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.Active, not recruitingNCT06116136Study sitePhase 1/Phase 2Start 2024-08
  23. A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsActive, not recruitingNCT06257264Study sitePhase 1Start 2024-03
  24. A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in ChinaCompletedNCT06585501Study siteStart 2024-08
  25. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaTerminatedNCT06206278Study sitePhase 2Start 2023-10
  26. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  27. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  28. Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)Active, not recruitingNCT05382364Study sitePhase 1Start 2022-06
  29. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  30. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsCompletedNCT04852679Study sitePhase 3Start 2021-05
  31. A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal JunctionCompletedNCT04661150Study sitePhase 2Start 2021-03
  32. Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)Active, not recruitingNCT04704934Study sitePhase 3Start 2021-05
  33. Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer TrialStatus unknownNCT04744649Study sitePhase 2Start 2021-03
  34. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  35. Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsStatus unknownNCT05019794Study sitePhase 2Start 2020-05
  36. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  37. Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid TumorsCompletedNCT04400383Study sitePhase 1Start 2020-06
  38. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  39. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  40. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Study sitePhase 3Start 2018-11
  41. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Study sitePhase 2Start 2018-09
  42. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)CompletedNCT03615326Study sitePhase 3Start 2018-10
  43. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Study sitePhase 3Start 2018-11
  44. BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction CarcinomaCompletedNCT03469557Study sitePhase 2Start 2017-07
  45. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal CancerCompletedNCT02898077Study sitePhase 3Start 2017-03
  46. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Study sitePhase 3Start 2017-02
  47. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  48. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2Status unknownNCT02356276Study sitePhase 3Start 2015-05
  49. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedNCT02178956Study sitePhase 3Start 2014-10
  50. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric CancerCompletedNCT01774786Study sitePhase 3Start 2013-06
  51. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04
  52. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)Status unknownNCT01609309Study sitePhase 3Start 2012-09
  53. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerTerminatedNCT01641939Study sitePhase 2/Phase 3Start 2012-09

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 156 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.7%.

Papers led
156
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
69
led by another institution
Papers led per year
2021: 222220212022: 232320222023: 232320232024: 373720242025: 47472025

4 hospitals in Harbin for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 69

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
    Phase
    Phase 2/Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07063745

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Wuhan, Xiamen

  2. Recruiting
    Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
    Phase
    Phase 3
    Started
    2026-01
    Posted
    Registry
    NCT07195695

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shijiazhuang, Suzhou, Taizhou, Tianjin, Wuhan, Xuzhou, Yangzhou, Zhengzhou

  3. Recruiting
    A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Posted
    Registry
    NCT07227025

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Harbin, Shanghai

  4. Recruiting
    A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07227597

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jiangmen, Nanchang, Shanghai, Taizhou

  5. Recruiting
    A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07253142

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesFuzhou, Guangzhou, Harbin, Hefei, Nanning, Shanghai, Wuhan, Xinxiang, Xuzhou

  6. Recruiting
    First in Human Study of SIM0610 in Solid Tumors
    Phase
    Phase 1
    Started
    2026-01
    Posted
    Registry
    NCT07348211

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChongqing, Harbin, Shanghai, Shenyang

  7. Recruiting
    A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07367529

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Yangzhou, Zhongshan

  8. Recruiting
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07416474

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai

  9. Recruiting
    DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07472517

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Xuzhou, Yangzhou, Zhengzhou

  10. Recruiting
    A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07622186

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Nanchang, Nanjing, Nanning, Shenyang, Taiyuan, Tianjin, Xi'an, Xiamen, Xiangyang, Zhengzhou

  11. Recruiting
    A Study of DS-3939a in Participants With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07739966

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Jinan, Shanghai, Taizhou, Tianjin, Wuhan, Zhengzhou

  12. Recruiting
    A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
    Phase
    Phase 1/Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07843940

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChengdu, Harbin, Shanghai

  13. Recruiting
    A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06568939

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesFuzhou, Harbin, Linyi, Nanchang, Nanning, Urumqi, Wuhan, Xi'an, Zhengzhou

  14. Recruiting
    Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06712355

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Shanghai, Shantou, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou

  15. Recruiting
    This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06758401

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Tianjin, Wenzhou, Wuhan, Xi'an, Xuzhou, Zhengzhou

  16. Recruiting
    A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT06793215

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nantong, Shanghai, Shantou, Wuhan

  17. Recruiting
    Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06801834

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Shanghai, Shenzhen, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xinxiang, Yangzhou, Zhengzhou

  18. Recruiting
    A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
    Phase
    Phase 1
    Started
    2025-02
    Posted
    Registry
    NCT06839105

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChangchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanchang, Shanghai, Shenyang, Wuhan

  19. Recruiting
    Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT06862869

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Lanzhou, Nanchang, Nanjing, Nantong, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Wuxi, Xi'an, Yinchuan, Zhanjiang, Zunyi

  20. Recruiting
    A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06875310

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou

  21. Recruiting
    Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06890598

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesAnyang, Beijing, Changsha, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang, Nanning, Shanghai, Shantou, Shenzhen, Suzhou, Taizhou, Tianjin, Wuhan, Xi'an

  22. Recruiting
    Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT06899126

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou

  23. Recruiting
    A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT06962865

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Linyi, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Yantai, Zhengzhou

  24. Recruiting
    A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT07010263

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Harbin, Jiangmen, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xinxiang, Yinchuan, Zhengzhou, Zunyi

  25. Recruiting
    A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07143045

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesChangchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shenyang, Shenzhen, Taiyuan, Tianjin, Wuhan, Xiamen, Yangzhou, Zhengzhou

  26. Recruiting
    A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07144280

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Wuhan, Xi'an, Xuzhou, Zhengzhou

  27. Recruiting
    A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07164170

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Wuhan, Xi'an, Zhengzhou

  28. Recruiting
    A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07169994

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang

  29. Recruiting
    A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07182682

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou

  30. Recruiting
    Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07185997

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou

  31. Recruiting
    A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07217301

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luzhou, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Xi'an, Xinxiang, Xuzhou, Zhengzhou

  32. Recruiting
    A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07218146

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  33. Recruiting
    A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2024-01
    Posted
    Registry
    NCT06179069

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Shanghai, Shenyang, Wuhan, Xi'an, Xiamen, Zhengzhou

  34. Recruiting
    A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06203210

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Shenyang, Tianjin, Urumqi, Wuhan, Xiangyang, Yantai, Zhengzhou

  35. Recruiting
    A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06345729

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Suzhou, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Zhengzhou

  36. Recruiting
    A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-04
    Posted
    Registry
    NCT06403735

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHarbin, Kunming, Nanchang, Shanghai

  37. Recruiting
    JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
    Phase
    Phase 3
    Started
    2024-08
    Posted
    Registry
    NCT06416410

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Wuxi, Xi'an, Zhengzhou

  38. Recruiting
    Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
    Phase
    Phase 3
    Started
    2024-06
    Posted
    Registry
    NCT06422143

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanchang, Shanghai, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen, Yangzhou, Zhengzhou

  39. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  40. Recruiting
    A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    Phase
    Phase 3
    Started
    2024-08
    Posted
    Registry
    NCT06452277

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanjing, Shanghai, Taizhou, Wuhan, Xiamen

  41. Recruiting
    A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06496490

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin, Jiangmen, Nanchang, Nanning, Shanghai, Tianjin, Xi'an, Zhengzhou, Zunyi

  42. Recruiting
    A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
    Phase
    Phase 3
    Started
    2024-10
    Posted
    Registry
    NCT06561386

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Xinxiang

  43. Recruiting
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06632262

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesChengdu, Guiyang, Hangzhou, Harbin, Jinan, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  44. Recruiting
    A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06668103

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangchun, Harbin, Shanghai, Wuhan

  45. Recruiting
    Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT07433283

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Haikou, Harbin, Shanghai, Zhengzhou

  46. Recruiting
    A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
    Phase
    Phase 1/Phase 2
    Started
    2023-06
    Posted
    Registry
    NCT05789082

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Harbin, Shanghai

  47. Recruiting
    A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT05920356

    Age 18 years to 100 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Weifang, Wuhan, Xi'an, Xiamen, Xiangyang, Zhengzhou

  48. Recruiting
    A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06010329

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou

  49. Recruiting
    Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT06095583

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Yinchuan, Zhengzhou

  50. Recruiting
    A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06119581

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiangyang, Yichang, Zhanjiang

  51. Recruiting
    Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06170788

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Shanghai, Shijiazhuang, Taizhou, Wuhan, Wuxi, Xiamen, Xiangyang, Xuzhou, Zhanjiang, Zhengzhou

  52. Recruiting
    A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
    Phase
    Phase 3
    Started
    2022-03
    Posted
    Registry
    NCT04928846

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  53. Recruiting
    Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2022-09
    Posted
    Registry
    NCT05168566

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Linyi, Nanjing, Shanghai, Shenyang, Wuhan, Zhengzhou

  54. Recruiting
    Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
    Phase
    Phase 1/Phase 2
    Started
    2022-04
    Posted
    Registry
    NCT05288205

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Harbin, Hefei, Hohhot, Jinan, Linyi, Shanghai, Shenyang, Shenzhen, Wuhan, Xiamen, Zhengzhou

  55. Recruiting
    A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2022-11
    Posted
    Registry
    NCT05498428

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Harbin, Shanghai, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai

  56. Recruiting
    Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
    Phase
    Phase 1
    Started
    2021-07
    Posted
    Registry
    NCT04886804

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou

  57. Recruiting
    A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
    Phase
    Phase 1
    Started
    2021-08
    Posted
    Registry
    NCT04913285

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHarbin, Linyi, Shanghai

  58. Recruiting
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Posted
    Registry
    NCT04930432

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  59. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Posted
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Shanghai, Shenyang, Taiyuan, Tianjin, Zhengzhou, Zhuhai

  60. Recruiting
    First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
    Phase
    Phase 1/Phase 2
    Started
    2021-10
    Posted
    Registry
    NCT05099172

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan, Nanjing, Shanghai, Taizhou

  61. Recruiting
    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
    Phase
    Phase 2/Phase 3
    Started
    2020-12
    Posted
    Registry
    NCT04613596

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  62. Recruiting
    Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
    Phase
    Phase 1/Phase 2
    Started
    2019-07
    Posted
    Registry
    NCT04270591

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Zhengzhou

  63. Not yet recruiting
    A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07550842

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangzhou, Harbin, Shanghai, Shenyang, Taizhou, Wuhan, Zhengzhou

  64. Not yet recruiting
    A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07623642

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin

  65. Not yet recruiting
    A Phase 2 Study of ABSK043 Combined With Osimertinib
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07710612

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesGuangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Taiyuan, Wuhan

  66. Not yet recruiting
    Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    Phase
    Phase 1
    Started
    2026-11
    Posted
    Registry
    NCT07912268

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Fuzhou, Harbin, Nanchang, Shanghai

  67. Not yet recruiting
    Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06885840

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Foshan, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Shenyang, Tianjin, Wuhan, Xi'an, Zhengzhou

  68. Not yet recruiting
    YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
    Phase
    Phase 3
    Started
    2023-05
    Posted
    Registry
    NCT05767892

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

  69. Not yet recruiting
    A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2023-11
    Posted
    Registry
    NCT05990127

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luoyang, Nanchang, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicineRadiation oncologyRadiology / nuclear medicine
Papers it led156
  1. Prognostic Value of Multiparameter Biomarkers in Pleural Effusion of Patients With Non-small Cell Lung Cancer for Predicting Survival Outcomes: A Prospective Cohort Study.2026American journal of clinical oncology
  2. A positive feedback loop between SERPINH1 and MMP-9/TGF-β1 promotes lung adenocarcinoma progression.2026Cell death and differentiation
  3. Real-world effectiveness and safety of treatment strategies for unresectable, driver-negative Stage III NSCLC: A retrospective multicentre study.2026International journal of cancer
  4. Cost-effectiveness analysis of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy as first-line treatment of metastatic non-squamous non-small cell lung cancer.2026Journal of chemotherapy (Florence, Italy)
  5. Pericardial Fat and Primary Tumor Radiomics for Predicting Occult N2 Disease and Survival in Clinical Stage I Non-Small Cell Lung Cancer: Multicenter Study and Biologic Correlation.2025AJR. American journal of roentgenology
  6. Targeting piRNA-137463 Inhibits Tumor Progression and Boosts Sensitivity to Immune Checkpoint Blockade via De Novo Cholesterol Biosynthesis in Lung Adenocarcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  7. Integrin β8 Facilitates Macrophage Infiltration and Polarization by Regulating CCL5 to Promote LUAD Progression.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  8. Implementing liquid biopsy NGS in stage III/IV NSCLC: clinical utility assessment from a real-world Chinese cohort.2025BMC cancerFree full text
  9. A CT-based radiomics nomogram incorporating adipose tissue to differentiate invasive adenocarcinomas among part-solid pulmonary nodules.2025BMC cancerFree full text
  10. Deep learning radiomics and mediastinal adipose tissue-based nomogram for preoperative prediction of postoperative‌ brain metastasis risk in non-small cell lung cancer.2025BMC cancerFree full text
  11. Disease burden of lung cancer attributable to metabolic and behavioral risks in China and globally from 1990 to 2021.2025BMC public healthFree full text
  12. m6A-modified EHD1 controls PD-L1 endosomal trafficking to modulate immune evasion and immunotherapy responses in lung adenocarcinoma.2025Cancer communications (London, England)Free full text
  13. Development and validation of nomograms to predict brain metastasis-free survival in lung and breast cancer.2025Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  14. MS4A1 regulates M1-polarized tumor-associated macrophage infiltration, angiogenesis, and cancer progression through the HIPPO pathway in lung adenocarcinoma.2025Cancer immunology, immunotherapy : CIIFree full text
  15. Multimodal Deep Learning Integrating Tumor Radiomics and Mediastinal Adiposity Improves Survival Prediction in Non-Small Cell Lung Cancer: A Prognostic Modeling Study.2025Cancer medicineFree full text
  16. Therapeutic efficacy of TMTP1-modified EVs in overcoming bone metastasis and immune resistance in PIK3CA mutant NSCLC.2025Cell death & diseaseFree full text
  17. M6A -mediated lncRNA SCIRT stability promotes NSCLC progression through binding to SFPQ and activating the PI3K/Akt pathway.2025Cellular and molecular life sciences : CMLSFree full text
  18. Application of random survival forest to establish a nomogram combining clinlabomics-score and clinical data for predicting brain metastasis in primary lung cancer.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoFree full text
  19. Correlation between radiologic feature and spread through air space in lung solid adenocarcinoma 30.0 mm or less in maximum diameter.2025Clinical imaging
  20. Prediction of PD-L1 expression in NSCLC patients using PET/CT radiomics and prognostic modelling for immunotherapy in PD-L1-positive NSCLC patients.2025Clinical radiology
  21. Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer.2025Critical reviews in oncology/hematology
  22. MFAP5 Strengthened the Stem Cell Features of Non-small Cell Lung Cancer Cells by Regulating the FBW/Sox9 Axis.2025Current pharmaceutical biotechnology
  23. Opsin3 regulates cell proliferation, migration, and apoptosis in lung adenocarcinoma via GPX3 pathway.2025European journal of medical researchFree full text
  24. Assessing the genetic estimates of the association between plasma caffeine and cancer risk through Mendelian randomization.2025European journal of nutrition
  25. Deep learning model using CT images for longitudinal prediction of benign and malignant ground-glass nodules.2025European journal of radiology
  26. Post-hoc analysis of real-world retrospective study on neoadjuvant chemotherapy combined with immunotherapy for stage I-III non-small cell lung cancer.2025Frontiers in immunologyFree full text
  27. Advancements in extensive-stage small cell lung cancer therapy: from molecular profiling to the advent of precision oncology.2025Frontiers in immunologyFree full text
  28. The Lung Cancer Immune Prognostic Score predicts pathologic complete response and survival in NSCLC patients receiving neoadjuvant immunochemotherapy.2025Frontiers in immunologyFree full text
  29. A comprehensive prognostic and immunological implications of Gremlin 1 in lung adenocarcinoma.2025Frontiers in immunologyFree full text
  30. Serum sphingosine-1-phosphate levels are associated with brain metastasis in EGFR-mutant lung adenocarcinoma.2025Future oncology (London, England)Free full text
  31. The role of exosomal PD-L1 in NSCLC immunotherapy.2025ImmunotherapyFree full text
  32. RUNX1 promotes NSCLC progression by ACP5/SMAD3-mediated M2 macrophage polarization.2025Inflammation research : official journal of the European Histamine Research Society ... [et al.]
  33. Development of a machine learning-based prognostic model for survival prediction in patients with lung cancer brain metastases using multicenter clinical data.2025International journal of medical informatics
  34. Molecular characterization of breast cancer and multiple primary malignancies: the latest application using unmarked quantitative proteomics.2025International journal of surgery (London, England)Free full text
  35. Peptide YY fragment PYY1-36 disrupts mitochondrial biogenesis via RBM43-dependent PGC-1α translation inhibition.2025Investigational new drugsFree full text
  36. Predictive classification of lung cancer pathological based on PET/CT radiomics.2025Japanese journal of radiology
  37. RBM10 deficiency promotes brain metastasis by modulating sphingolipid metabolism in a BBB model of EGFR mutant lung adenocarcinoma.2025Journal of experimental & clinical cancer research : CRFree full text
  38. Overcoming acquired immunotherapy resistance in non-small cell lung cancer using ginsenoside Rb1-loaded, peptide-enhanced exosome delivery systems.2025Journal of nanobiotechnologyFree full text
  39. RBM15 recruits myeloid-derived suppressor cells via the m6A-IGF2BP3/CBR3-AS1/miR-409-3p/CXCL1 axis, facilitating radioresistance in non-small-cell lung cancer.2025Journal of translational medicineFree full text
  40. Neoadjuvant immunotherapy in early-stage NSCLC: navigating biomarker dilemmas and special population challenges.2025Lung cancer (Amsterdam, Netherlands)
  41. Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models.2025Molecular cancer therapeuticsFree full text
  42. 19F MR Imaging of Dule Lung Cancer Models with Two Administration Methods of PFC Nanoparticles.2025Molecular imaging and biology
  43. RFX2-BNIP3 axis-driven adaptive mitophagy promotes resistance to ACK1-targeted therapy in non-small cell lung cancer.2025Oncogene
  44. RNA‑binding protein MBNL1 regulates tumor growth, chemosensitivity and antitumor immunity in lung adenocarcinoma by controlling the expression of tumor suppressor RNF125.2025Oncology reportsFree full text
  45. Dual biomarkers CT-based deep learning model incorporating intrathoracic fat for discriminating benign and malignant pulmonary nodules in multi-center cohorts.2025Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)
  46. Landscape of the intratumoral microbiota acting on the tumor immune microenvironment in LUAD and LUSC.2025Physiological genomics
  47. CT Predictors of Angiolymphatic Invasion in Non-Small Cell Lung Cancer 30 mm or Smaller.2025Radiology
  48. ZNF184-mediated transcriptional activation of SAE1 drives the cell cycle entry and immune evasion in non-small cell lung cancer.2025Respiratory researchFree full text
  49. In vivo self-assembled bispecific fluorescence probe for early detection of bladder cancer and metastasis.2025Science bulletin
  50. Efficacy and toxicity of stereotactic radiotherapy combined with third-generation EGFR-TKIs and immunotherapy in patients with brain metastases from non-small cell lung cancer.2025Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]Free full text
  51. Comprehensive profiling of T-cell exhaustion signatures and establishment of a prognostic model in lung adenocarcinoma through integrated RNA-sequencing analysis.2025Technology and health care : official journal of the European Society for Engineering and Medicine
  52. m6A-Modified SNRPA Controls Alternative Splicing of ERCC1 Exon 8 to Induce Cisplatin Resistance in Lung Adenocarcinoma.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  53. Ubiquitin-Specific Protease 22 Plays a Key Role in Increasing Extracellular Vesicle Secretion and Regulating Cell Motility of Lung Adenocarcinoma.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  54. Clinical significance of the combined systemic immune-inflammatory index and prognostic nutritional index in predicting the prognosis of patients with extensive-stage small-cell lung cancer receiving immune-combination chemotherapy.2024BMC cancerFree full text
  55. Deep learning-based characterization of pathological subtypes in lung invasive adenocarcinoma utilizing 18F-deoxyglucose positron emission tomography imaging.2024BMC cancerFree full text
  56. Development and validation of a preoperative CT‑based radiomics nomogram to differentiate tuberculosis granulomas from lung adenocarcinomas: an external validation study.2024BMC cancerFree full text
  57. Red blood cell distribution width is associated with sarcopenia risk in early-stage non-small cell lung cancer.2024BMC cancerFree full text
  58. FERMT1 promotes cell migration and invasion in non-small cell lung cancer via regulating PKP3-mediated activation of p38 MAPK signaling.2024BMC cancerFree full text
  59. Dexmedetomidine promotes necroptosis by upregulating PARP1 in non-small cell lung cancer.2024Biotechnology & genetic engineering reviews
  60. Correlation analysis between camrelizumab trough concentration levels and efficacy or safety in East Asian patients with advanced lung cancer.2024Cancer chemotherapy and pharmacology
  61. An Integrated Nomogram Combining Deep Learning and Radiomics for Predicting Malignancy of Pulmonary Nodules Using CT-Derived Nodules and Adipose Tissue: A Multicenter Study.2024Cancer medicineFree full text
  62. The clinical, molecular, and therapeutic implications of time from primary diagnosis to brain metastasis in lung and breast cancer patients.2024Cancer medicineFree full text
  63. A novel iTreg-related signature for prognostic prediction in lung adenocarcinoma.2024Cancer scienceFree full text
  64. Multi-scale and multi-view network for lung tumor segmentation.2024Computers in biology and medicine
  65. METnet: A novel deep learning model predicting MET dysregulation in non-small-cell lung cancer on computed tomography images.2024Computers in biology and medicine
  66. Predicting the Prognosis of Lung Cancer Patients Treated with Intensitymodulated Radiotherapy based on Radiomic Features.2024Current medical imaging
  67. MicroRNA-522-3p promotes brain metastasis in non-small cell lung cancer by targeting Tensin 1 and modulating blood-brain barrier permeability.2024Experimental cell research
  68. Preoperative glucose-to-lymphocyte ratio predicts survival in cancer.2024Frontiers in endocrinologyFree full text
  69. Multimodal data deep learning method for predicting symptomatic pneumonitis caused by lung cancer radiotherapy combined with immunotherapy.2024Frontiers in immunologyFree full text
  70. Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study.2024Frontiers in immunologyFree full text
  71. Tumor-derived exosomal PD-L1: a new perspective in PD-1/PD-L1 therapy for lung cancer.2024Frontiers in immunologyFree full text
  72. Spatial tertiary lymphoid structures imply response to anti-PD-1 plus anlotinib in advanced non-small cell lung cancer.2024Immunology
  73. LncRNA HAR1A inhibits non-small cell lung cancer growth by downregulating c-MYC transcripts and facilitating its proteasomal degradation.2024International immunopharmacology
  74. Combination of the cuproptosis inducer disulfiram and anti‑PD‑L1 abolishes NSCLC resistance by ATP7B to regulate the HIF‑1 signaling pathway.2024International journal of molecular medicineFree full text
  75. Draw on advantages and avoid disadvantages: CT-derived individualized radiomic signature for predicting chemo-radiotherapy sensitivity in unresectable advanced non-small cell lung cancer.2024Journal of cancer research and clinical oncologyFree full text
  76. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.2024Journal of cancer research and clinical oncologyFree full text
  77. Safety of one 8.5-Fr pigtail catheter for postoperative continuous open gravity drainage after uniportal video-assisted thoracoscopic surgery pneumonectomy.2024Journal of cardiothoracic surgeryFree full text
  78. Investigation of mediastinal lymph node dissection in clinical stage IA pure-solid non-small cell lung cancer patients.2024Journal of cardiothoracic surgeryFree full text
  79. Radiotherapy combined with anti-PD-1 and TKI for primary cardiac angiosarcoma considering the joint assessment of TLSs and PD-L1: a case report.2024Journal of cardiothoracic surgeryFree full text
  80. Clinical Manifestation, Risk Factors, and Immune Checkpoint Inhibitor Rechallenge of Checkpoint Inhibitor-Associated Pneumonitis in Patients With Lung Cancer.2024Journal of immunotherapy (Hagerstown, Md. : 1997)
  81. An innovative electrohydrodynamics-driven SERS platform for molecular stratification and treatment monitoring of lung cancer.2024Journal of materials chemistry. B
  82. Sleep disturbance as a poor prognostic predictor in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A prospective study.2024Journal of psychosomatic research
  83. Dynamic analysis of predictive biomarkers for radiation therapy efficacy in non-small cell lung cancer patients by next-generation sequencing based on blood specimens.2024Pathology, research and practice
  84. SP1 undergoes phase separation and activates RGS20 expression through super-enhancers to promote lung adenocarcinoma progression.2024Proceedings of the National Academy of Sciences of the United States of AmericaFree full text
  85. CT Predictors of Visceral Pleural Invasion in Patients with Non-Small Cell Lung Cancers 30 mm or Smaller.2024Radiology
  86. Influence of malnutrition according to the glim criteria on the chemotherapy toxicities in patients with advanced lung cancer.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  87. Comparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma.2024Thoracic cancerFree full text
  88. Prognostic factors in patients with first diagnosis of hepatocellular carcinoma presenting with pulmonary metastasis and construction of a clinical prediction model.2024Updates in surgery
  89. Development and validation of 18F-FDG PET/CT radiomics-based nomogram to predict visceral pleural invasion in solid lung adenocarcinoma.2023Annals of nuclear medicine
  90. The prediction of distant metastasis risk for male breast cancer patients based on an interpretable machine learning model.2023BMC medical informatics and decision makingFree full text
  91. Sec61γ is a vital protein in the endoplasmic reticulum membrane promoting tumor metastasis and invasion in lung adenocarcinoma.2023British journal of cancerFree full text
  92. LINC00669 promotes lung adenocarcinoma growth by stimulating the Wnt/β-catenin signaling pathway.2023Cancer medicineFree full text
  93. M6A RNA methylation-mediated RMRP stability renders proliferation and progression of non-small cell lung cancer through regulating TGFBR1/SMAD2/SMAD3 pathway.2023Cell death and differentiationFree full text
  94. A Novel PRKAR1A::MET Fusion Dramatic Response to Crizotinib in a Patient with Unresectable Lung Cancer.2023Clinical lung cancer
  95. Preoperative small airway dysfunction is associated with skeletal muscle loss in early-stage non-small cell lung cancer.2023Clinical nutrition (Edinburgh, Scotland)
  96. Deep learning for predicting the risk of immune checkpoint inhibitor-related pneumonitis in lung cancer.2023Clinical radiologyRCT
  97. IGF2BP3 Worsens Lung Cancer through Modifying Long Non-coding RNA CERS6-AS1/microRNA-1202 Axis.2023Current medicinal chemistry
  98. miR-4732-3p prevents lung cancer progression via inhibition of the TBX15/TNFSF11 axis.2023Epigenomics
  99. Efficacy of immunotherapy as second-line or later-line therapy and prognostic significance of KRAS or TP53 mutations in advanced non-small cell lung cancer patients.2023European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  100. Establishment and validation of nomograms to predict survival probability of advanced malignant pleural mesothelioma based on the SEER database and a Chinese medical institution.2023Frontiers in endocrinologyFree full text
  101. Effect of concomitant antibiotics use on patient outcomes and adverse effects in patients treated with ICIs.2023Immunopharmacology and immunotoxicology
  102. The significance of spread through air spaces in the prognostic assessment model of stage I lung adenocarcinoma and the exploration of its invasion mechanism.2023Journal of cancer research and clinical oncologyFree full text
  103. Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.2023Journal of chemotherapy (Florence, Italy)
  104. Predictive Value of Gene Databases in Discovering New Biomarkers and New Therapeutic Targets in Lung Cancer.2023Medicina (Kaunas, Lithuania)Free full text
  105. Improvement of ACK1-targeted therapy efficacy in lung adenocarcinoma using chloroquine or bafilomycin A1.2023Molecular medicine (Cambridge, Mass.)Free full text
  106. The Predictive Model Construction for Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy.2023Technology in cancer research & treatmentFree full text
  107. Sevoflurane attenuates proliferative and migratory activity of lung cancer cells via mediating the microRNA-100-3p/sterol O-Acyltransferase 1 axis.2023The Chinese journal of physiology
  108. Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma.2023The Journal of biological chemistryFree full text
  109. microRNA-651-5p affects the proliferation, migration, and invasion of lung cancer cells by regulating Calmodulin 2 expression.2023The clinical respiratory journalFree full text
  110. NIR-IIb fluorescence-image guided synergistic surgery/starvation/chemodynamic therapy: an innovative treatment paradigm for malignant non-small cell lung cancers.2023TheranosticsFree full text
  111. Analysis between macrophage-related genes with prognosis and tumor microenvironment in non-small cell lung cancer.2023Yi chuan = Hereditas
  112. Expression characteristic, immune signature, and prognosis value of EFNA family identified by multi-omics integrative analysis in pan-cancer.2022BMC cancerFree full text
  113. Preoperative PDW levels predict pulmonary metastasis in patients with hepatocellular carcinoma.2022BMC cancerFree full text
  114. Prediction of prognosis and immunotherapy response with a robust immune-related lncRNA pair signature in lung adenocarcinoma.2022Cancer immunology, immunotherapy : CIIFree full text
  115. Surgical Trauma-induced CCL2 Upregulation Mediates Lung Cancer Progression by Promoting Treg Recruitment in Mice and Patients.2022Cancer investigation
  116. Long noncoding RNA CBR3-AS1 mediates tumorigenesis and radiosensitivity of non-small cell lung cancer through redox and DNA repair by CBR3-AS1 /miR-409-3p/SOD1 axis.2022Cancer letters
  117. TMEM139 prevents NSCLC metastasis by inhibiting lysosomal degradation of E-cadherin.2022Cancer scienceFree full text
  118. miR-596-3p suppresses brain metastasis of non-small cell lung cancer by modulating YAP1 and IL-8.2022Cell death & diseaseFree full text
  119. A novel EHD1/CD44/Hippo/SP1 positive feedback loop potentiates stemness and metastasis in lung adenocarcinoma.2022Clinical and translational medicineFree full text
  120. Prognostic Value of Combination of Controlling Nutritional Status and Tumor Marker in Patients with Radical Non-Small-Cell Lung Cancer.2022Disease markersFree full text
  121. CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung Adenocarcinoma.2022Frontiers in immunologyFree full text
  122. Long-term safety and efficacy of bisphosphonate therapy in advanced lung cancer with bone metastasis.2022Future oncology (London, England)
  123. Knockdown of LINC00511 decreased cisplatin resistance in non-small cell lung cancer by elevating miR-625 level to suppress the expression of leucine rich repeat containing eight volume-regulated anion channel subunit E.2022Human & experimental toxicology
  124. TRIM44 promotes BRCA1 functions in HR repair to induce Cisplatin Chemoresistance in Lung Adenocarcinoma by Deubiquitinating FLNA.2022International journal of biological sciencesFree full text
  125. RNA-binding motif protein 10 represses tumor progression through the Wnt/β- catenin pathway in lung adenocarcinoma.2022International journal of biological sciencesFree full text
  126. Peripheral Tumor Location Predicts a Favorable Prognosis in Patients with Resected Small Cell Lung Cancer.2022International journal of clinical practiceFree full text
  127. Prognostic and Immunological Implications of FAM72A in Pan-Cancer and Functional Validations.2022International journal of molecular sciencesFree full text
  128. Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial.2022JAMA network openRCTFree full text
  129. Technical aspects and early results of uniportal video-assisted thoracoscopic complex segmentectomy: a 30 case-series study.2022Journal of cardiothoracic surgeryFree full text
  130. Characterization of the prognostic and diagnostic values of ALKBH family members in non-small cell lung cancer.2022Pathology, research and practice
  131. Radiomics combined with clinical features in distinguishing non-calcifying tuberculosis granuloma and lung adenocarcinoma in small pulmonary nodules.2022PeerJFree full text
  132. Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma.2022Respiratory researchFree full text
  133. Sarcopenia is an independent risk factor for depression in patients with advanced lung cancer.2022Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  134. Patient-Generated Subjective Global Assessment (PG-SGA) predicts length of hospital stay in lung adenocarcinoma patients.2022The British journal of nutritionFree full text
  135. MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts.2021AgingFree full text
  136. Identification of downstream signaling cascades of ACK1 and prognostic classifiers in non-small cell lung cancer.2021AgingFree full text
  137. Knock-down of microRNA miR-556-5p increases cisplatin-sensitivity in non-small cell lung cancer (NSCLC) via activating NLR family pyrin domain containing 3 (NLRP3)-mediated pyroptotic cell death.2021BioengineeredFree full text
  138. Combined inhibition of ACK1 and AKT shows potential toward targeted therapy against KRAS-mutant non-small-cell lung cancer.2021Bosnian journal of basic medical sciencesFree full text
  139. High BASP1 Expression is Associated with Poor Prognosis and Promotes Tumor Progression in Human Lung Adenocarcinoma.2021Cancer investigation
  140. A feedback circuit comprising EHD1 and 14-3-3ζ sustains β-catenin/c-Myc-mediated aerobic glycolysis and proliferation in non-small cell lung cancer.2021Cancer letters
  141. Dynamic biomarkers indicate the immunological benefits provided by Ganoderma spore powder in post-operative breast and lung cancer patients.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoRCT
  142. Incidence risk of PD-1/PD-L1-related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials.2021European journal of clinical pharmacology
  143. PIGF and Flt-1 on the surface of macrophages induces the production of TGF-β1 by polarized tumor-associated macrophages to promote lung cancer angiogenesis.2021European journal of pharmacology
  144. The lncRNA ALMS1-IT1 may promote malignant progression of lung adenocarcinoma via AVL9-mediated activation of the cyclin-dependent kinase pathway.2021FEBS open bioFree full text
  145. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.2021Frontiers in immunologyFree full text
  146. The Important Role of N6-methyladenosine RNA Modification in Non-Small Cell Lung Cancer.2021GenesFree full text
  147. Clinical outcomes of patients taking first-generation EGFR-TKIs may predict the benefits afforded by osimertinib in EGFR T790M-mutant NSCLC patients.2021International journal of clinical practice
  148. Stereotactic body radiation therapy for non-small cell lung cancer using the non-coplanar radiation of Cyberknife and Varian linac.2021Journal of X-ray science and technology
  149. High systemic immune-inflammation index is a predictor of poor prognosis in patients with nonsmall cell lung cancer and bone metastasis.2021Journal of cancer research and therapeutics
  150. Risk factors for lymph node metastasis and surgical scope in patients with cN0 non-small cell lung cancer: a single-center study in China.2021Journal of cardiothoracic surgeryFree full text
  151. Engineering of gemcitabine coated nano-graphene oxide sheets for efficient near-infrared radiation mediated in vivo lung cancer photothermal therapy.2021Journal of photochemistry and photobiology. B, Biology
  152. UBE2T promotes autophagy via the p53/AMPK/mTOR signaling pathway in lung adenocarcinoma.2021Journal of translational medicineFree full text
  153. Development of metastasis-associated seven gene signature for predicting lung adenocarcinoma prognosis using single-cell RNA sequencing data.2021Mathematical biosciences and engineering : MBE
  154. FOXO3A-induced LINC00926 suppresses breast tumor growth and metastasis through inhibition of PGK1-mediated Warburg effect.2021Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  155. CXCR1 correlates to poor outcomes of EGFR-TKI against advanced non-small cell lung cancer by activating chemokine and JAK/STAT pathway.2021Pulmonary pharmacology & therapeutics
  156. High prognostic nutritional index (PNI) as a positive prognostic indicator for non-small cell lung cancer patients with bone metastasis.2021The clinical respiratory journal
Chinese-language papers (not in the count)3
  1. [Research Progress on the Protective Effect of Intestinal Flora on 
Radiation-induced Lung Injury in Thoracic Tumors].2023Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  2. [Progress of Immune Checkpoint Inhibitors 
in the Treatment of Advanced Pulmonary Neuroendocrine Tumors].2021Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  3. [Research Progress of Immune Checkpoint Inhibitors 
in Malignant Pleural Mesothelioma].2021Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
All its trials on ClinicalTrials.gov, any status161
  1. Study of DC-CTL Combined With CIK for Advanced Solid TumorStatus unknownNCT03047525Lead (inferred)Phase 1/Phase 2Start 2017-02
  2. A Study of DS-3939a in Participants With Solid TumorsRecruitingNCT07739966Study sitePhase 1/Phase 2Start 2026-10
  3. A Clinical Trial on the Efficacy and Safety of TQB6411 for InjectionRecruitingNCT07367529Study sitePhase 1/Phase 2Start 2026-02
  4. A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionRecruitingNCT07063745Study sitePhase 2/Phase 3Start 2026-01
  5. A Phase 2 Study of ABSK043 Combined With OsimertinibNot yet recruitingNCT07710612Study sitePhase 2Start 2026-08
  6. A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)RecruitingNCT07227597Study sitePhase 1/Phase 2Start 2026-01
  7. A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT07622186Study sitePhase 2Start 2026-07
  8. DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyRecruitingNCT07472517Study sitePhase 3Start 2026-04
  9. A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.Not yet recruitingNCT07623642Study sitePhase 2Start 2026-06
  10. A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)RecruitingNCT07843940Study sitePhase 1/Phase 2Start 2026-10
  11. A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung CancerRecruitingNCT07253142Study sitePhase 2Start 2026-02
  12. RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)RecruitingNCT07416474Study sitePhase 3Start 2026-04
  13. First in Human Study of SIM0610 in Solid TumorsRecruitingNCT07348211Study sitePhase 1Start 2026-01
  14. A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung CancerNot yet recruitingNCT07550842Study sitePhase 1Start 2026-06
  15. Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT07912268Study sitePhase 1Start 2026-11
  16. Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsRecruitingNCT07195695Study sitePhase 3Start 2026-01
  17. A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung CancerRecruitingNCT07227025Study sitePhase 1/Phase 2Start 2026-03
  18. Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerRecruitingNCT06801834Study sitePhase 3Start 2025-04
  19. A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) MetastasesRecruitingNCT07143045Study siteStart 2025-12
  20. A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLCRecruitingNCT06962865Study sitePhase 2Start 2025-06
  21. Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.Not yet recruitingNCT06885840Study sitePhase 2Start 2025-03
  22. Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant TherapyRecruitingNCT06862869Study siteStart 2025-04
  23. A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)RecruitingNCT06875310Study sitePhase 3Start 2025-04
  24. A Phase 2 Clinical Study of Combination Therapy With ABSK043 and GlecirasibRecruitingNCT07164170Study sitePhase 2Start 2025-09
  25. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.RecruitingNCT06758401Study sitePhase 3Start 2025-07
  26. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsRecruitingNCT07185997Study sitePhase 3Start 2025-12
  27. A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical SurgeryRecruitingNCT07182682Study sitePhase 3Start 2025-12
  28. Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerRecruitingNCT06712355Study sitePhase 3Start 2025-02
  29. A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsRecruitingNCT07169994Study sitePhase 1/Phase 2Start 2025-09
  30. A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced MalignanciesRecruitingNCT06839105Study sitePhase 1Start 2025-02
  31. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerRecruitingNCT06793215Study sitePhase 3Start 2025-10
  32. A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)RecruitingNCT07218146Study sitePhase 3Start 2025-11
  33. A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)RecruitingNCT07144280Study sitePhase 3Start 2025-09
  34. Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerRecruitingNCT06899126Study sitePhase 3Start 2025-10
  35. A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation TherapyRecruitingNCT07010263Study sitePhase 3Start 2025-06
  36. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerRecruitingNCT06890598Study sitePhase 3Start 2025-03
  37. A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung CancerRecruitingNCT07217301Study sitePhase 3Start 2025-11
  38. A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT06568939Study sitePhase 2Start 2025-01
  39. A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%RecruitingNCT06561386Study sitePhase 3Start 2024-10
  40. A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT06452277Study sitePhase 3Start 2024-08
  41. A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene AbnormalityRecruitingNCT06496490Study sitePhase 2Start 2024-08
  42. A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerRecruitingNCT06203210Study sitePhase 3Start 2024-05
  43. A Phase 2 Clinical Study of ABSK061 and ABSK043RecruitingNCT06632262Study sitePhase 2Start 2024-11
  44. A Phase 2 Clinical Study of Combination Therapy With ABSK043 and FirmonertinibRecruitingNCT06668103Study sitePhase 2Start 2024-11
  45. A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)RecruitingNCT06345729Study sitePhase 3Start 2024-05
  46. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  47. Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid TumorRecruitingNCT07433283Study sitePhase 1/Phase 2Start 2024-11
  48. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]RecruitingNCT06422143Study sitePhase 3Start 2024-06
  49. A Study of ZL-1310 in Subjects With Small Cell Lung CancerRecruitingNCT06179069Study sitePhase 1Start 2024-01
  50. A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid TumorsRecruitingNCT06403735Study sitePhase 1Start 2024-04
  51. JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C MutationRecruitingNCT06416410Study sitePhase 3Start 2024-08
  52. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerRecruitingNCT06119581Study sitePhase 3Start 2023-12
  53. A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)RecruitingNCT05920356Study sitePhase 3Start 2023-11
  54. A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung CancerNot yet recruitingNCT05990127Study sitePhase 3Start 2023-11
  55. A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLCRecruitingNCT06010329Study sitePhase 2Start 2023-12
  56. A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C MutationRecruitingNCT05789082Study sitePhase 1/Phase 2Start 2023-06
  57. Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)RecruitingNCT06095583Study sitePhase 3Start 2023-11
  58. YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsNot yet recruitingNCT05767892Study sitePhase 3Start 2023-05
  59. Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)RecruitingNCT06170788Study sitePhase 3Start 2023-12
  60. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT04928846Study sitePhase 3Start 2022-03
  61. Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C MutationRecruitingNCT05288205Study sitePhase 1/Phase 2Start 2022-04
  62. A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerRecruitingNCT05498428Study sitePhase 2Start 2022-11
  63. Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung CancerRecruitingNCT05168566Study sitePhase 2Start 2022-09
  64. A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsRecruitingNCT04913285Study sitePhase 1Start 2021-08
  65. Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid TumorsRecruitingNCT04930432Study sitePhase 1/Phase 2Start 2021-09
  66. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)RecruitingNCT04886804Study sitePhase 1Start 2021-07
  67. First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT05099172Study sitePhase 1/Phase 2Start 2021-10
  68. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Study sitePhase 1/Phase 2Start 2021-11
  69. Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7RecruitingNCT04613596Study sitePhase 2/Phase 3Start 2020-12
  70. Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung CancerRecruitingNCT04270591Study sitePhase 1/Phase 2Start 2019-07
  71. A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLCActive, not recruitingNCT06883630Study sitePhase 1Start 2025-03
  72. Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and ImmunotherapyTerminatedNCT06924606Study sitePhase 2Start 2025-07
  73. A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)Active, not recruitingNCT07005128Study sitePhase 3Start 2025-08
  74. A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT07005336Study sitePhase 2Start 2025-01
  75. Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active, not recruitingNCT06710132Study sitePhase 1/Phase 2Start 2025-01
  76. Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibActive, not recruitingNCT06120140Study sitePhase 2Start 2024-02
  77. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid TumorsActive, not recruitingNCT06586515Study sitePhase 1Start 2024-09
  78. A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer PatientsStatus unknownNCT06469879Study sitePhase 3Start 2024-09
  79. ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung CancerCompletedNCT06498479Study sitePhase 3Start 2024-07
  80. A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsActive, not recruitingNCT06257264Study sitePhase 1Start 2024-03
  81. A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerActive, not recruitingNCT06711900Study sitePhase 3Start 2024-10
  82. Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)Active, not recruitingNCT06305754Study sitePhase 3Start 2024-06
  83. Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of TreatmentActive, not recruitingNCT06502977Study sitePhase 2Start 2024-08
  84. A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung CancerActive, not recruitingNCT06225804Study sitePhase 1Start 2024-02
  85. A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06448312Study sitePhase 3Start 2024-06
  86. A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic AlterationsActive, not recruitingNCT06644768Study sitePhase 1/Phase 2Start 2024-10
  87. Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard TreatmentActive, not recruitingNCT06151574Study sitePhase 3Start 2024-02
  88. A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung CancerActive, not recruitingNCT06984588Study sitePhase 2/Phase 3Start 2024-03
  89. PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung CancerActive, not recruitingNCT06616532Study sitePhase 3Start 2024-11
  90. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsActive, not recruitingNCT05899608Study sitePhase 3Start 2023-10
  91. A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With SurgeryCompletedNCT05872763Study siteStart 2023-08
  92. A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung CancerCompletedNCT05635708Study sitePhase 2Start 2023-02
  93. Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)Active, not recruitingNCT05555732Study sitePhase 3Start 2023-01
  94. A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)Active, not recruitingNCT05816252Study sitePhase 2Start 2023-04
  95. A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung CancerCompletedNCT06029127Study sitePhase 2Start 2023-10
  96. A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLCActive, not recruitingNCT05844150Study sitePhase 2Start 2023-06
  97. Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)Active, not recruitingNCT06074588Study sitePhase 3Start 2023-11
  98. Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)Active, not recruitingNCT05609968Study sitePhase 3Start 2023-02
  99. H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLCStatus unknownNCT05552781Study sitePhase 1/Phase 2Start 2022-08
  100. Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)TerminatedNCT05226598Study sitePhase 3Start 2022-03
  101. Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsActive, not recruitingNCT05215340Study sitePhase 3Start 2022-03
  102. A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)Active, not recruitingNCT05668988Study sitePhase 3Start 2022-12
  103. A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung CancerActive, not recruitingNCT05297890Study sitePhase 2Start 2022-05
  104. A Study of PM8002 in Combination With Chemotherapy in Patients With SCLCActive, not recruitingNCT05879068Study sitePhase 2Start 2022-05
  105. A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung CancerActive, not recruitingNCT05353257Study sitePhase 3Start 2022-05
  106. Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)Active, not recruitingNCT05224141Study sitePhase 3Start 2022-03
  107. A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05388669Study sitePhase 3Start 2022-08
  108. Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT05195632Study sitePhase 2Start 2022-06
  109. Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung CancerStatus unknownNCT05416775Study sitePhase 1/Phase 2Start 2022-08
  110. AP-L1898 Capsule in Patients With Non-small Cell Lung CancerTerminatedNCT04993391Study sitePhase 1/Phase 2Start 2021-07
  111. Bintrafusp Alfa Program Rollover StudyCompletedNCT05061823Study sitePhase 3Start 2021-12
  112. A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) MetastasesActive, not recruitingNCT04603807Study sitePhase 3Start 2021-09
  113. A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib FailureActive, not recruitingNCT04988295Study sitePhase 3Start 2021-11
  114. Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerTerminatedNCT04921358Study sitePhase 3Start 2021-07
  115. A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung CancerTerminatedNCT04746924Study sitePhase 3Start 2021-05
  116. Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)Active, not recruitingNCT05712902Study sitePhase 2Start 2021-07
  117. Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung CancerCompletedNCT05014815Study sitePhase 2Start 2021-11
  118. A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung CancerTerminatedNCT04308785Study sitePhase 2Start 2021-12
  119. A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04819100Study sitePhase 3Start 2021-12
  120. Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)TerminatedNCT04738487Study sitePhase 3Start 2021-04
  121. Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)Active, not recruitingNCT04656652Study sitePhase 3Start 2020-12
  122. A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung CancerCompletedNCT04426825Study sitePhase 2Start 2020-09
  123. Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT04665856Study sitePhase 3Start 2020-12
  124. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  125. A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung CancerStatus unknownNCT04398940Study sitePhase 2Start 2020-08
  126. Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based ChemotherapyCompletedNCT04447118Study sitePhase 3Start 2020-09
  127. Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerCompletedNCT04205812Study sitePhase 3Start 2020-09
  128. HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung CancerStatus unknownNCT04750083Study sitePhase 2/Phase 3Start 2020-09
  129. A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)Status unknownNCT04234607Study sitePhase 3Start 2020-01
  130. A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerActive, not recruitingNCT04194944Study sitePhase 3Start 2020-02
  131. A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung CancerCompletedNCT04294810Study sitePhase 3Start 2020-03
  132. A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)CompletedNCT04194203Study sitePhase 3Start 2020-04
  133. A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 InsertionsActive, not recruitingNCT04538664Study sitePhase 3Start 2020-10
  134. Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04379635Study sitePhase 3Start 2020-05
  135. A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT04487080Study sitePhase 3Start 2020-09
  136. Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT04005716Study sitePhase 3Start 2019-07
  137. Cancer Genome Atlas of China:Lung CancerStatus unknownNCT04266483Study siteStart 2019-11
  138. A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung CancerStatus unknownNCT04439890Study sitePhase 3Start 2019-08
  139. A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in ChinaCompletedNCT03909971Study sitePhase 2Start 2019-04
  140. Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer(NSCLC)CompletedNCT03693547Study sitePhase 2Start 2019-04
  141. A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung CancerStatus unknownNCT04641754Study sitePhase 2Start 2019-03
  142. Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)Active, not recruitingNCT03974022Study sitePhase 1/Phase 2Start 2019-07
  143. A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLCStatus unknownNCT03668496Study sitePhase 3Start 2018-11
  144. A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung CancerCompletedNCT03594747Study sitePhase 3Start 2018-07
  145. A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung CancerTerminatedNCT03516084Study sitePhase 3Start 2018-08
  146. A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung CancerCompletedNCT03663205Study sitePhase 3Start 2018-07
  147. Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerActive, not recruitingNCT03539536Study sitePhase 2Start 2018-10
  148. A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)TerminatedNCT03033511Study sitePhase 3Start 2017-02
  149. Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03358875Study sitePhase 3Start 2017-11
  150. A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing ChemotherapyCompletedNCT02813785Study sitePhase 3Start 2016-07
  151. A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) PatientsStatus unknownNCT04237805Study sitePhase 1/Phase 2Start 2016-11
  152. A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)CompletedNCT02763579Study sitePhase 3Start 2016-06
  153. A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02838420Study sitePhase 3Start 2016-08
  154. Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)CompletedNCT02568267Study sitePhase 2Start 2015-11
  155. Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in ChinaCompletedNCT02458651Study siteStart 2015-06
  156. Avelumab in First-line NSCLC (JAVELIN Lung 100)CompletedNCT02576574Study sitePhase 3Start 2015-10
  157. A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung CancerCompletedNCT02031744Study sitePhase 3Start 2014-01
  158. Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung CancerStatus unknownNCT02215356Study sitePhase 2Start 2014-08
  159. A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous ChemotherapyCompletedNCT01364012Study sitePhase 3Start 2011-05
  160. Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR MutationsStatus unknownNCT01410214Study sitePhase 2Start 2011-05
  161. Loading Dose or Standard Dose of Intravenous Ibandronate in Treating Patients With Lung Cancer and Skeletal MetastasisTerminatedNCT00492843Study sitePhase 4Start 2007-07

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 27 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.5%.

Papers led
27
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
14
led by another institution
Papers led per year
2021: 5520212022: 4420222023: 8820232024: 5520242025: 552025

3 hospitals in Harbin for pancreatic cancer192 hospitals in China for pancreatic cancer

Open trials with this hospital 14

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07640295

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Harbin, Nanjing, Shanghai, Taiyuan, Wuhan, Zhengzhou

  2. Recruiting
    Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06821503

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Harbin, Nanchang, Nanjing, Shanghai, Shenyang, Tianjin, Xi'an, Zhengzhou

  3. Recruiting
    A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06953999

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHangzhou, Harbin, Shanghai

  4. Recruiting
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07066657

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Harbin, Shanghai, Wuhan, Zhengzhou

  5. Recruiting
    Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07823049

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yangzhou, Yinchuan, Zhengzhou

  6. Recruiting
    A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
    Phase
    Phase 2/Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06361888

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Suzhou, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  7. Recruiting
    A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-04
    Posted
    Registry
    NCT06403735

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHarbin, Kunming, Nanchang, Shanghai

  8. Recruiting
    Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT07433283

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Haikou, Harbin, Shanghai, Zhengzhou

  9. Recruiting
    A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT06008288

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Zhengzhou

  10. Recruiting
    A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT06111274

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Harbin, Shanghai, Wuhan

  11. Recruiting
    Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
    Phase
    Phase 1/Phase 2
    Started
    2022-04
    Posted
    Registry
    NCT05288205

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Harbin, Hefei, Jinan, Shanghai, Shenyang, Shenzhen, Wuhan, Xiamen, Zhengzhou

  12. Recruiting
    Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
    Phase
    Phase 3
    Started
    2022-12
    Posted
    Registry
    NCT05653453

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHarbin, Shanghai

  13. Recruiting
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2021-06
    Posted
    Registry
    NCT04900818

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  14. Not yet recruiting
    A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07623642

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyRadiation oncologyGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)
Papers it led27
  1. TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1-Mediated Arachidonic Acid Metabolism.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Exploring the genetic link between gastroesophageal reflux disease and pancreatic cancer: insights from Mendelian randomization.2025BMC cancerFree full text
  3. The combination of gemcitabine and albumin-bound paclitaxel effectively inhibits de novo lipogenesis in pancreatic cancer cells by targeting the AMPK/SREBP1 pathway.2025Biochemical pharmacology
  4. Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild-Type Pancreatic Cancer.2025Cancer scienceFree full text
  5. Engineered exosomes: a promising approach for overcoming challenges in pancreatic cancer therapy.2025Journal of nanobiotechnologyFree full text
  6. Age-period-cohort analysis of global, regional, and national pancreatic cancer incidence, mortality, and disability-adjusted life years, 1990-2019.2024BMC cancerFree full text
  7. Meaningful nomograms based on systemic immune inflammation index predicted survival in metastatic pancreatic cancer patients receiving chemotherapy.2024Cancer medicineFree full text
  8. VDR promotes pancreatic cancer progression in vivo by activating CCL20-mediated M2 polarization of tumor associated macrophage.2024Cell communication and signaling : CCSFree full text
  9. BNIP3+ fibroblasts associated with hypoxia and inflammation predict prognosis and immunotherapy response in pancreatic ductal adenocarcinoma.2024Journal of translational medicineFree full text
  10. Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma.2024The oncologistFree full text
  11. Comprehensive analysis identifies cuproptosis-related gene DLAT as a potential prognostic and immunological biomarker in pancreatic adenocarcinoma.2023BMC cancerFree full text
  12. Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer.2023BMC cancerRCTFree full text
  13. Prediction scores of postoperative liver metastasis and long-term survival of pancreatic head cancer based on the distance between the mesenteric vessels and tumor, preoperative serum carbohydrate antigen 19-9 level, and lymph node metastas2023Cancer medicineFree full text
  14. Splicing transcriptome-wide association study to identify splicing events for pancreatic cancer risk.2023Carcinogenesis
  15. HNF4G stimulates the development of pancreatic cancer by promoting IGF2BP2 transcription.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  16. Inhibition of autophagy promotes sonodynamic therapy-induced apoptosis of pancreatic cancer cells.2023Folia histochemica et cytobiologica
  17. Extracellular vesicle-derived LINC00511 promotes glycolysis and mitochondrial oxidative phosphorylation of pancreatic cancer through macrophage polarization by microRNA-193a-3p-dependent regulation of plasminogen activator urokinase.2023Immunopharmacology and immunotoxicology
  18. Prognostic value of albumin-bilirubin score in pancreatic cancer patients after pancreatoduodenectomy with liver metastasis following radiofrequency ablation.2023Pathology oncology research : PORFree full text
  19. The outcome of intravenous and inhalation anesthesia after pancreatic cancer resection: a retrospective study.2022BMC anesthesiologyFree full text
  20. HOXB9 blocks cell cycle progression to inhibit pancreatic cancer cell proliferation through the DNMT1/RBL2/c-Myc axis.2022Cancer letters
  21. Classification and Prognosis Analysis of Pancreatic Cancer Based on DNA Methylation Profile and Clinical Information.2022GenesFree full text
  22. GPR120 promotes metastasis but inhibits tumor growth in pancreatic ductal adenocarcinoma.2022Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  23. Determination of Deformable Image Registration Algorithms for Accumulating Dose in Carbon-ion Radiotherapy for Pancreatic Cancer.2021Anticancer research
  24. Silencing of FTX suppresses pancreatic cancer cell proliferation and invasion by upregulating miR-513b-5p.2021BMC cancerFree full text
  25. The combined analgesic effect of pregabalin and morphine in the treatment of pancreatic cancer pain, a retrospective study.2021Cancer medicineFree full text
  26. Systemic Inflammatory Biomarkers, Especially Fibrinogen to Albumin Ratio, Predict Prognosis in Patients with Pancreatic Cancer.2021Cancer research and treatmentFree full text
  27. Adaptive planning based on single beam optimization in passive scattering carbon ion radiotherapy for patients with pancreatic cancer.2021Radiation oncology (London, England)Free full text
Chinese-language papers (not in the count)1
  1. [The impact of the dosage of intraoperative opioids on postoperative survival outcomes in patients with pancreatic cancer].2022Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status25
  1. A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.Not yet recruitingNCT07623642Study sitePhase 2Start 2026-06
  2. Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene AlterationsRecruitingNCT07640295Study sitePhase 1/Phase 2Start 2026-07
  3. Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort CRecruitingNCT06821503Study sitePhase 1/Phase 2Start 2025-04
  4. Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic TherapyRecruitingNCT07823049Study sitePhase 3Start 2025-07
  5. A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic CancerRecruitingNCT06953999Study sitePhase 3Start 2025-06
  6. A Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsRecruitingNCT07066657Study sitePhase 1Start 2025-07
  7. A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic CancerRecruitingNCT06361888Study sitePhase 2/Phase 3Start 2024-05
  8. Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid TumorRecruitingNCT07433283Study sitePhase 1/Phase 2Start 2024-11
  9. A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid TumorsRecruitingNCT06403735Study sitePhase 1Start 2024-04
  10. A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.RecruitingNCT06008288Study sitePhase 2Start 2023-10
  11. A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic CancerRecruitingNCT06111274Study sitePhase 2Start 2023-10
  12. Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic CancerRecruitingNCT05653453Study sitePhase 3Start 2022-12
  13. Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C MutationRecruitingNCT05288205Study sitePhase 1/Phase 2Start 2022-04
  14. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsRecruitingNCT04900818Study sitePhase 1Start 2021-06
  15. Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active, not recruitingNCT06710132Study sitePhase 1/Phase 2Start 2025-01
  16. MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid TumorsActive, not recruitingNCT06586515Study sitePhase 1Start 2024-09
  17. A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)Active, not recruitingNCT06360354Study sitePhase 1Start 2024-05
  18. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  19. Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid TumorsCompletedNCT04400383Study sitePhase 1Start 2020-06
  20. A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic CancerStatus unknownNCT03721744Study sitePhase 2/Phase 3Start 2018-10
  21. Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)CompletedNCT03377491Study sitePhase 3Start 2018-05
  22. A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic AdenocarcinomaCompletedNCT02993731Study sitePhase 3Start 2016-12
  23. Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)CompletedNCT02568267Study sitePhase 2Start 2015-11
  24. A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic CancerCompletedNCT02395016Study sitePhase 3Start 2015-04
  25. Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic CancerStatus unknownNCT02278458Study sitePhase 1Start 2014-10

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 168 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 1.0%.

Papers led
168
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
38
led by another institution
Papers led per year
2021: 252520212022: 303020222023: 292920232024: 424220242025: 37372025

4 hospitals in Harbin for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 39

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07752550

    Age 18 years to 100 years; women only (registered criteria)

    Led by Harbin Medical University Cancer HospitalHarbin

  2. Recruiting
    A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07281976

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Guangzhou, Harbin, Nanjing, Shenyang, Zhengzhou

  3. Recruiting
    A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07347600

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Weifang, Wuhan, Xi'an, Xiamen, Yangzhou, Zhengzhou

  4. Recruiting
    Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07383818

    Age 18 years to 70 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 4 listed hospitals as study sitesHangzhou, Harbin, Hefei, Shanghai, Xi'an

  5. Recruiting
    BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07492641

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou

  6. Recruiting
    A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07876557

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Jinan, Lanzhou, Nanchang, Nanjing, Qingdao, Shenyang, Shijiazhuang, Taiyuan, Weifang, Wuhan, Yinchuan, Zhengzhou

  7. Recruiting
    A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
    Phase
    Phase 1/Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06679036

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Zhengzhou

  8. Recruiting
    A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06790693

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Nanning, Tianjin, Urumqi, Xi'an, Xiangyang

  9. Recruiting
    A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06891833

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesAnyang, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Luoyang, Nanchang, Nanning, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  10. Recruiting
    A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06966700

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Hangzhou, Harbin, Hefei, Jinan, Nanjing, Nanning, Shanghai, Urumqi, Wuhan, Xi'an, Xiamen, Zhengzhou

  11. Recruiting
    Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06977893

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 9 listed hospitals as study sitesHangzhou, Harbin, Hefei, Nanchang, Shanghai, Urumqi, Xi'an, Zhengzhou

  12. Recruiting
    A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07043725

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou

  13. Recruiting
    JS207 Combination Therapy in Triple-negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07045311

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Dalian, Hangzhou, Harbin, Hefei, Nanjing, Qingdao, Shenyang, Shijiazhuang, Urumqi, Wuhan, Xi'an, Zhengzhou

  14. Recruiting
    TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07047365

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 44 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guiyang, Haikou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Luzhou, Nanchang, Nanchong, Nanjing, Nanning, Ningbo, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Xi'an, Xiangyang, Xining, Xinxiang, Xuzhou, Zhengzhou

  15. Recruiting
    A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
    Phase
    Phase 3
    Started
    2025-08
    Posted
    Registry
    NCT07062965

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Wenzhou, Wuhan, Xi'an

  16. Recruiting
    A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07169994

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Meizhou, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang

  17. Recruiting
    A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07174336

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Shanghai, Shantou, Tianjin, Wuhan

  18. Recruiting
    An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-12
    Posted
    Registry
    NCT07222267

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Xiamen

  19. Recruiting
    Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
    Phase
    N/A
    Started
    2025-10
    Posted
    Registry
    NCT07469267

    Age 18 years to Not stated; women only (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 12 listed hospitals as study sitesChangsha, Guiyang, Hangzhou, Harbin, Jinan, Ningbo, Shanghai, Shijiazhuang, Tianjin, Wuhan

  20. Recruiting
    A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT07673029

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou

  21. Recruiting
    A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06210776

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Kunming, Luoyang, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Urumqi, Weifang, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai

  22. Recruiting
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    Phase
    Phase 1/Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06324357

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou

  23. Recruiting
    The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06452706

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesHangzhou, Harbin, Shanghai, Urumqi, Wuhan, Xi'an

  24. Recruiting
    A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-08
    Posted
    Registry
    NCT06503783

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shanghai

  25. Recruiting
    Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
    Phase
    Phase 2
    Started
    2024-06
    Posted
    Registry
    NCT06611813

    Age 18 years to 75 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 6 listed hospitals as study sitesHangzhou, Harbin, Hefei, Shanghai, Urumqi, Zhengzhou

  26. Recruiting
    Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
    Phase
    Phase 2
    Started
    2024-10
    Posted
    Registry
    NCT06682195

    Age 18 years to 70 years; women only (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 10 listed hospitals as study sitesHangzhou, Harbin, Hefei, Nanchang, Shanghai, Taiyuan, Urumqi, Xi'an, Zhengzhou

  27. Recruiting
    Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT05860465

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanjing, Shenyang, Shijiazhuang, Tianjin, Xi'an, Yinchuan

  28. Recruiting
    Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
    Phase
    Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT05872347

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Guangzhou, Hangzhou, Harbin, Hefei, Luoyang, Nanjing, Nanning, Shijiazhuang, Tianjin, Urumqi, Wuhan, Xiangyang, Yinchuan, Zhengzhou

  29. Recruiting
    JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06079983

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  30. Recruiting
    A Study of YL202 in Selected Patients With Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06107686

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou

  31. Recruiting
    BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-12
    Posted
    Registry
    NCT06120283

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shanghai, Shenyang

  32. Recruiting
    A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2022-09
    Posted
    Registry
    NCT06954961

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin

  33. Recruiting
    Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
    Phase
    Phase 4
    Started
    2021-07
    Posted
    Registry
    NCT04136782

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical University; 3 listed hospitals as study sitesChangchun, Harbin, Shenyang

  34. Recruiting
    Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
    Phase
    Not given
    Started
    2021-07
    Posted
    Registry
    NCT04476485

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical University; 3 listed hospitals as study sitesChangchun, Harbin, Shenyang

  35. Not yet recruiting
    Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07487519

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHarbin

  36. Not yet recruiting
    A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07560124

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Harbin

  37. Not yet recruiting
    A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
    Phase
    Phase 2
    Started
    2026-06
    Posted
    Registry
    NCT07623642

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin

  38. Not yet recruiting
    A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06354114

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHarbin

  39. Enrolling by invitation
    A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07376629

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesAnyang, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyRadiology / nuclear medicineRadiation oncologyPathology / laboratory medicine
Papers it led168
  1. Integrating Deep Feature Extraction and MRI Radiomics for Survival Prediction in Breast Cancer After Neoadjuvant Chemotherapy.2026Academic radiology
  2. Proteogenomic Characterization Reveals Subtype-Specific Therapeutic Potential for HER2-Low Breast Cancer.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Biomimetic Organic Nanozyme as Tumor Vaccines for Targeted Suppression of Ammonia-Induced T Lymphocyte Death to Augment Breast Cancer Immunotherapy.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  4. Spatial molecular analyses reveal key features associated with response to KN026 in advanced HER2-positive breast cancer.2026British journal of cancerFree full text
  5. TQB2440 compared with reference pertuzumab for HER2-positive, ER/PgR-negative, early or locally advanced breast cancer: a multicenter, randomized, double-blind, parallel-controlled, phase III equivalence trial.2026ESMO openRCTFree full text
  6. Novel MRI-based Hyper-Fused Radiomics for Predicting Pathologic Complete Response to Neoadjuvant Therapy in Breast Cancer.2025Academic radiology
  7. Biomimetic Single-Atom Nanozyme for Dual Starvation-Enhanced Breast Cancer Immunotherapy.2025Advanced healthcare materials
  8. Camouflaged Nanozymes with Oxidation-Promoting Activities Triggering Ferroptosis for Radio-Immunotherapy.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  9. Machine learning and SHAP value interpretation for predicting the response to neoadjuvant chemotherapy and long-term clinical outcomes in Chinese female breast cancer.2025Annals of medicineFree full text
  10. Lactate dehydrogenase a is a crucial biomarker that affects the prognosis, chemotherapy effect, and immune infiltration of breast cancer.2025BMC women's healthFree full text
  11. Novel models based on machine learning to predict the prognosis of metaplastic breast cancer.2025Breast (Edinburgh, Scotland)Free full text
  12. Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial.2025Cancer communications (London, England)Free full text
  13. Development and validation of nomograms to predict brain metastasis-free survival in lung and breast cancer.2025Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  14. An Approach for Differential Diagnosis of Breast Tumors by ctDNA Methylation Sequencing.2025Cancer medicineFree full text
  15. Lnc-TPT1-AS1/CBP/ATIC Axis Mediated Purine Metabolism Activation Promotes Breast Cancer Progression.2025Cancer scienceFree full text
  16. LHPP-P38 MAPK/ERK-ETS1 Axis Negative Feedback Signaling Restrains Progression in Breast Cancer.2025Cancer scienceFree full text
  17. ZMIZ1 lactylation induces tamoxifen resistance in breast cancer through increasing transcriptional activity of Nanog to impact cell stemness and cholesterol uptake.2025Cell biology and toxicologyFree full text
  18. In Triple-Negative Breast Cancer: Correlation Among Metabolic Syndrome, S100A7/cPLA2 Expression and the Efficacy of Neoadjuvant Chemotherapy.2025Clinical breast cancer
  19. The combination of flaxseed lignans and PD-1/ PD-L1 inhibitor inhibits breast cancer growth via modulating gut microbiome and host immunity.2025Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  20. Tumor vascular normalization by B7-H3 blockade augments T lymphocyte-mediated antitumor immunity.2025European journal of pharmacology
  21. Pan-immune-inflammation value predicts survival in inflammatory breast cancer patients.2025Experimental biology and medicine (Maywood, N.J.)Free full text
  22. Association of the inflammatory microenvironment of obesity with pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy.2025Frontiers in endocrinologyFree full text
  23. Necrosis by sodium overload-associated genes TRPM4 and SLC9A1: biological roles and clinical implications in breast cancer progression.2025Frontiers in immunologyFree full text
  24. Integrating deep learning features from mammography with SHAP values for a machine learning model predicting over 5-year recurrence of breast ductal carcinoma In Situ post-lumpectomy.2025Frontiers in immunologyFree full text
  25. Association of microtubule-based processes gene expression with immune microenvironment and its predictive value for drug response in oestrogen receptor-positive breast cancer.2025Frontiers in immunologyFree full text
  26. Current state of cancer immunity cycle: new strategies and challenges of using precision hydrogels to treat breast cancer.2025Frontiers in immunologyFree full text
  27. Fundamental knowledge and research regarding the role of immunity in triple-negative breast cancer from 2014-2024: A bibliometric analysis.2025Human vaccines & immunotherapeuticsFree full text
  28. SMC4 promotes immune evasion by inhibiting endogenous interferon signaling and upregulating PD-L1 expression in triple negative breast cancer.2025International immunopharmacology
  29. Exosomal miR-3529-3p increases the sensitivity of trastuzumab via Wnt/β-catenin signaling pathway by targeting HOOK3.2025International immunopharmacology
  30. PSMD14 promotes breast cancer progression by reducing K63-linked ubiquitination on FOXM1 and activating the PI3K/AKT/mTOR pathway.2025International journal of biological macromolecules
  31. HSP90 inhibitor-loaded hollow mesoporous nanoparticles for enhanced synergistic mild photothermal/chemotherapy in triple negative breast cancer.2025International journal of biological macromolecules
  32. Molecular characterization of breast cancer and multiple primary malignancies: the latest application using unmarked quantitative proteomics.2025International journal of surgery (London, England)Free full text
  33. FTO activates PD-L1 promotes immunosuppression in breast cancer via the m6A/YTHDF3/PDK1 axis under hypoxic conditions.2025Journal of advanced researchFree full text
  34. H4K79 and H4K91 histone lactylation, newly identified lactylation sites enriched in breast cancer.2025Journal of experimental & clinical cancer research : CRFree full text
  35. Machine learning-based identification of kbhb-affected tumor cell subsets as prognostic and therapeutic targets in breast cancer.2025Journal of translational medicineFree full text
  36. Application of mass cytometry in the immune microenvironment of breast cancer.2025Medical oncology (Northwood, London, England)
  37. Comprehensive analysis of the biological functions and prognostic significance of GDI1 in breast cancer.2025MedicineFree full text
  38. Preoperative inflammatory status as a positive prognostic factor for triple-negative breast cancer patients receiving neoadjuvant therapy.2025MedicineFree full text
  39. Transcriptome-wide analysis reveals potential roles of CFD and ANGPTL4 in fibroblasts regulating B cell lineage for extracellular matrix-driven clustering and novel avenues for immunotherapy in breast cancer.2025Molecular medicine (Cambridge, Mass.)Free full text
  40. Harnessing the inflammatory signature: a review for biomarkers in inflammatory breast cancer.2025QJM : monthly journal of the Association of Physicians
  41. Implementation of personalized multidisciplinary neuropathy management program for chemotherapy-induced peripheral neuropathy symptoms in breast cancer patients.2025The International journal of neuroscience
  42. Extratumoral Signs of Malignant Nonspiculate and Noncalcified Masses on Mammography: Are They Associated With Prognostic Factors in Breast Cancer?2025The breast journalFree full text
  43. Cold Exposure Therapy Sensitizes Nanodrug-Mediated Radioimmunotherapy of Breast Cancer.2024ACS nano
  44. Can we skip invasive biopsy of sentinel lymph nodes? A preliminary investigation to predict sentinel lymph node status using PET/CT-based radiomics.2024BMC cancerFree full text
  45. Preoperative platelet distribution width predicts bone metastasis in patients with breast cancer.2024BMC cancerFree full text
  46. Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy.2024BMC cancerFree full text
  47. Investigation of correlation between shear wave elastography and lymphangiogenesis in invasive breast cancer and diagnosis of axillary lymph node metastasis.2024BMC cancerFree full text
  48. Diagnostic value of applying preoperative breast ultrasound and clinicopathologic features to predict axillary lymph node burden in early invasive breast cancer: a study of 1247 patients.2024BMC cancerFree full text
  49. Development of predictive models for pathological response status in breast cancer after neoadjuvant therapy based on peripheral blood inflammatory indexes.2024BMC women's healthFree full text
  50. An antihypertensive drug-AT1 inhibitor attenuated BRCA development promoted by chronic psychological stress via Ang II/PARP1/FN1 pathway.2024Biochimica et biophysica acta. Molecular basis of disease
  51. Nanobubble-mediated co-delivery of siTRIM37 and IR780 for gene and sonodynamic combination therapy against triple negative breast cancer.2024Biomedical materials (Bristol, England)
  52. PSAT1 Promotes Metastasis via p-AKT/SP1/ITGA2 Axis in Estrogen Receptor-Negative Breast Cancer Cell.2024BiomoleculesFree full text
  53. Subcutaneous fat predicts bone metastasis in breast cancer: A novel multimodality-based deep learning model.2024Cancer biomarkers : section A of Disease markersFree full text
  54. Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients.2024Cancer chemotherapy and pharmacology
  55. Identification of Novel Anoikis-Related Gene Signatures to Predict the Prognosis, Immune Microenvironment, and Drug Sensitivity of Breast Cancer Patients.2024Cancer control : journal of the Moffitt Cancer CenterFree full text
  56. The clinical, molecular, and therapeutic implications of time from primary diagnosis to brain metastasis in lung and breast cancer patients.2024Cancer medicineFree full text
  57. Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes.2024Cancer research and treatmentFree full text
  58. A comprehensive overview of metaplastic breast cancer: Features and treatments.2024Cancer scienceFree full text
  59. Ginsenoside Rg3 overcomes tamoxifen resistance through inhibiting glycolysis in breast cancer cells.2024Cell biology international
  60. Tumor suppressor KEAP1 promotes HSPA9 degradation, controlling mitochondrial biogenesis in breast cancer.2024Cell reports
  61. Calcium-sensing receptor and NF-κB pathways in TN breast cancer contribute to cancer-induced cardiomyocyte damage via activating neutrophil extracellular traps formation.2024Cellular and molecular life sciences : CMLSFree full text
  62. The predictive value of systemic immune-inflammatory markers before and after treatment for pathological complete response in patients undergoing neoadjuvant therapy for breast cancer: a retrospective study of 1994 patients.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  63. Combination of DCE-MRI and NME-DWI via Deep Neural Network for Predicting Breast Cancer Molecular Subtypes.2024Clinical breast cancer
  64. CyTOF analysis revealed platelet heterogeneity in breast cancer patients received T-DM1 treatment.2024Clinical immunology (Orlando, Fla.)
  65. MRI-based vector radiomics for predicting breast cancer HER2 status and its changes after neoadjuvant therapy.2024Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
  66. Proteomic, single-cell and bulk transcriptomic analysis of plasma and tumor tissues unveil core proteins in response to anti-PD-L1 immunotherapy in triple negative breast cancer.2024Computers in biology and medicine
  67. Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy.2024Diagnostic pathologyFree full text
  68. Integration of transcriptomics and machine learning for insights into breast cancer: exploring lipid metabolism and immune interactions.2024Frontiers in immunologyFree full text
  69. Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2- breast cancer.2024International immunopharmacology
  70. The Gustave Roussy Immune score (GRIm score) as a novel prognostic score for early breast cancer patients: A real-world retrospective study.2024International journal of medical sciencesFree full text
  71. RNA-Seq Reveals the Mechanism of Pyroptosis Induced by Oxygen-Enriched IR780 Nanobubbles-Mediated Sono-Photodynamic Therapy.2024International journal of nanomedicineFree full text
  72. TME-Responsive Nanoplatform with Glutathione Depletion for Enhanced Tumor-Specific Mild Photothermal/Gene/Ferroptosis Synergistic Therapy.2024International journal of nanomedicineFree full text
  73. Comparison of the efficacy of taxanes with carboplatin and anthracyclines with taxanes in neoadjuvant chemotherapy for stage II-III triple negative breast cancer: a retrospective analysis.2024Journal of cancer research and clinical oncologyFree full text
  74. Recent advances in caspase-3, breast cancer, and traditional Chinese medicine: a review.2024Journal of chemotherapy (Florence, Italy)
  75. NAT10/ac4C/JunB facilitates TNBC malignant progression and immunosuppression by driving glycolysis addiction.2024Journal of experimental & clinical cancer research : CRFree full text
  76. Adoptive cell immunotherapy for breast cancer: harnessing the power of immune cells.2024Journal of leukocyte biology
  77. A Channel-Dimensional Feature-Reconstructed Deep Learning Model for Predicting Breast Cancer Molecular Subtypes on Overall b-Value Diffusion-Weighted MRI.2024Journal of magnetic resonance imaging : JMRI
  78. Responds to the Comments on "A Channel-Dimensional Feature-Reconstructed Deep Learning Model for Predicting Breast Cancer Molecular Subtypes on Overall b-Value Diffusion-Weighted MRI".2024Journal of magnetic resonance imaging : JMRI
  79. Transcription Impairment of TMEM208 by ZBTB14 Suppresses Breast cancer Radiotherapy Resistance.2024Journal of mammary gland biology and neoplasiaFree full text
  80. The potential of lenvatinib in breast cancer therapy.2024Medical oncology (Northwood, London, England)
  81. Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.2024Molecular cancerFree full text
  82. Clinicopathological Characteristics of Breast Cancer Patients with HER-2 Low Expression Receiving Neoadjuvant Therapy.2024Oncology
  83. The immune regulation and therapeutic potential of the SMAD gene family in breast cancer.2024Scientific reportsFree full text
  84. Calcium-sensing Receptor, a Potential Biomarker Revealed by Large-scale Public Databases and Experimental Verification in Metastatic Breast Cancer.2024Technology in cancer research & treatmentFree full text
  85. Pectoralis muscle predicts distant metastases in breast cancer by deep learning radiomics.2023Acta radiologica (Stockholm, Sweden : 1987)
  86. Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial.2023BMC cancerFree full text
  87. Automated Breast Ultrasound (ABUS)-based radiomics nomogram: an individualized tool for predicting axillary lymph node tumor burden in patients with early breast cancer.2023BMC cancerFree full text
  88. The prediction of distant metastasis risk for male breast cancer patients based on an interpretable machine learning model.2023BMC medical informatics and decision makingFree full text
  89. Ferroptosis induction via targeting metabolic alterations in triple-negative breast cancer.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  90. FN1 mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer.2023Breast cancer research and treatment
  91. Albumin-bilirubin score predicts trastuzumab resistance in HER2-positive breast cancer.2023Cancer biomarkers : section A of Disease markersFree full text
  92. Lower subcutaneous fat index predicts bone metastasis in breast cancer.2023Cancer biomarkers : section A of Disease markersFree full text
  93. Cytoplasmic YAP1-mediated ESCRT-III assembly promotes autophagic cell death and is ubiquitinated by NEDD4L in breast cancer.2023Cancer communications (London, England)Free full text
  94. Homologous recombination deficiency prediction using low-pass whole genome sequencing in breast cancer.2023Cancer genetics
  95. RMI2 is a novel prognostic and predictive biomarker for breast cancer.2023Cancer medicineFree full text
  96. Prediction of pathological complete response to neoadjuvant chemotherapy in patients with breast cancer using a combination of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging.2023Cancer medicineFree full text
  97. LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1-TINCR-USP20-PD-L1 axis.2023Cell death & diseaseFree full text
  98. The effectiveness of ultrasound-guided core needle biopsy in detecting lymph node metastases in the axilla in patients with breast cancer: systematic review and meta-analysis.2023Clinics (Sao Paulo, Brazil)Free full text
  99. Sufentanil inhibits the metastasis and immune response of breast cancer via mediating the NF-κB pathway.2023Immunopharmacology and immunotoxicology
  100. Evaluation of HER-2 positive breast cancer treated with dual-targeted treatment of trastuzumab plus pertuzumab.2023Immunopharmacology and immunotoxicology
  101. Ultrasound Triggered Tumor Metabolism Suppressor Induces Tumor Starvation for Enhanced Sonodynamic Immunotherapy of Breast Cancer.2023International journal of nanomedicineFree full text
  102. Correlation analysis between androgen receptor and the clinicopathological features and prognosis of mammary Paget's disease.2023Journal of cancer research and clinical oncologyFree full text
  103. Naples score: a novel prognostic biomarker for breast cancer patients undergoing neoadjuvant chemotherapy.2023Journal of cancer research and clinical oncologyFree full text
  104. Clinical characteristics and pathologic complete response (pCR) rate after neoadjuvant chemotherapy in postpartum women with breast cancer.2023Journal of cancer research and clinical oncologyFree full text
  105. The tremendous clinical potential of the microbiota in the treatment of breast cancer: the next frontier.2023Journal of cancer research and clinical oncologyFree full text
  106. Clinicopathological characteristics and prognosis of triple-negative breast cancer invasive ductal carcinoma with ductal carcinoma in situ.2023Journal of cancer research and clinical oncologyFree full text
  107. Comparison of Dynamic Contrast-Enhanced MRI and Non-Mono-Exponential Model-Based Diffusion-Weighted Imaging for the Prediction of Prognostic Biomarkers and Molecular Subtypes of Breast Cancer Based on Radiomics.2023Journal of magnetic resonance imaging : JMRI
  108. Single-cell RNA sequencing reveals small extracellular vesicles derived from malignant cells that contribute to angiogenesis in human breast cancers.2023Journal of translational medicineFree full text
  109. Identification of Genes Associated with Prognosis and Immunotherapy Prediction in Triple-Negative Breast Cancer via M1/M2 Macrophage Ratio.2023Medicina (Kaunas, Lithuania)Free full text
  110. Targeting mitochondrial dynamics by AZD5363 in triple-negative breast cancer MDA-MB-231 cell-derived spheres.2023Naunyn-Schmiedeberg's archives of pharmacologyFree full text
  111. The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo.2023Pharmacological research
  112. Early Prediction of Response to Neoadjuvant Chemotherapy Using Quantitative Parameters on Automated Breast Ultrasound Combined with Contrast-Enhanced Ultrasound in Breast Cancer.2023Ultrasound in medicine & biology
  113. Prediction of nonsentinel lymph node metastasis in breast cancer patients based on machine learning.2023World journal of surgical oncologyFree full text
  114. Differences in ultrasonographic features between males and females with breast cancer of the luminal A and luminal B molecular subtypes.2022Asia-Pacific journal of clinical oncology
  115. Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy.2022BMC cancerFree full text
  116. Prediction model of axillary lymph node status using automated breast ultrasound (ABUS) and ki-67 status in early-stage breast cancer.2022BMC cancerFree full text
  117. Systematic analysis of the expression and prognostic value of ITPR1 and correlation with tumor infiltrating immune cells in breast cancer.2022BMC cancerFree full text
  118. High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine.2022BMC cancerFree full text
  119. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.2022BMC medicineFree full text
  120. Deep learning radiomics under multimodality explore association between muscle/fat and metastasis and survival in breast cancer patients.2022Briefings in bioinformatics
  121. Serum amyloid A 1 induces suppressive neutrophils through the Toll-like receptor 2-mediated signaling pathway to promote progression of breast cancer.2022Cancer scienceFree full text
  122. Nano Carbon Tracing-based Treatment of Breast Cancer Lymphadenectomy and Nursing Intervention of Postoperative Lymphedema.2022Cellular and molecular biology (Noisy-le-Grand, France)RCT
  123. LncRNA RP11-214F16.8 drives breast cancer tumorigenesis via a post-translational repression on NISCH expression.2022Cellular signalling
  124. The Pretreatment Systemic Inflammation Response Index as a Useful Prognostic Factor is Better Than Lymphocyte to Monocyte Ratio in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.2022Clinical breast cancer
  125. Value of shear wave elasticity in predicting the efficacy of neoadjuvant chemotherapy in different molecular types.2022Clinical imaging
  126. Investigation of the Mechanism of hsa_circ_000 1429 Adsorbed miR-205 to Regulate KDM4A and Promote Breast Cancer Metastasis.2022Contrast media & molecular imagingFree full text
  127. A Novel Inflammatory and Nutritional Prognostic Scoring System for Nonpathological Complete Response Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.2022Disease markersFree full text
  128. The link between aberrant splicing and B cell infiltration in breast cancer hormone therapy.2022Endocrine-related cancer
  129. Performance of novel deep learning network with the incorporation of the automatic segmentation network for diagnosis of breast cancer in automated breast ultrasound.2022European radiology
  130. Combining Immune-Related Genes For Delineating the Extracellular Matrix and Predicting Hormone Therapy and Neoadjuvant Chemotherapy Benefits In Breast Cancer.2022Frontiers in immunologyFree full text
  131. Computer-aided classification of MRI for pathological complete response to neoadjuvant chemotherapy in breast cancer.2022Future oncology (London, England)
  132. Revealing the Potential Markers of N(4)-Acetylcytidine through acRIP-seq in Triple-Negative Breast Cancer.2022GenesFree full text
  133. Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis.2022Immunopharmacology and immunotoxicology
  134. USF1-ATRAP-PBX3 Axis Promote Breast Cancer Glycolysis and Malignant Phenotype by Activating AKT/mTOR Signaling.2022International journal of biological sciencesFree full text
  135. Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial.2022JAMA network openRCTFree full text
  136. Intratumor expanded T cell clones can be non-sentinel lymph node derived in breast cancer revealed by single-cell immune profiling.2022Journal for immunotherapy of cancerFree full text
  137. A Novel Necroptosis-Associated lncRNA Signature Can Impact the Immune Status and Predict the Outcome of Breast Cancer.2022Journal of immunology researchFree full text
  138. TPI1 activates the PI3K/AKT/mTOR signaling pathway to induce breast cancer progression by stabilizing CDCA5.2022Journal of translational medicineFree full text
  139. Long non-coding RNA ANRIL promotes chemoresistance in triple-negative breast cancer via enhancing aerobic glycolysis.2022Life sciences
  140. Characterized the diversity of ABCB1 subtypes in immunogenomic landscape for predicting the drug response in breast cancer.2022Methods (San Diego, Calif.)
  141. Single cell profiling of primary and paired metastatic lymph node tumors in breast cancer patients.2022Nature communicationsFree full text
  142. Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression.2022Pharmacology & therapeutics
  143. Prediction of Axillary Lymph Node Metastasis in Invasive Breast Cancer by Sound Touch Elastography.2022Ultrasound in medicine & biology
  144. Expression and prognostic values of ARID family members in breast cancer.2021AgingFree full text
  145. GABARAP suppresses EMT and breast cancer progression via the AKT/mTOR signaling pathway.2021AgingFree full text
  146. The application of personalized rehabilitation exercises in the postoperative rehabilitation of breast cancer patients.2021Annals of palliative medicine
  147. Clinical Significance of Oncoplastic Breast-Conserving Surgery and Application of Volume-Displacement Technique.2021Annals of plastic surgery
  148. Highly penetrating nanobubble polymer enhances LINC00511-siRNA delivery for improving the chemosensitivity of triple-negative breast cancer.2021Anti-cancer drugs
  149. Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters.2021BMC cancerFree full text
  150. Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients.2021Breast cancer research : BCRFree full text
  151. The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte.2021Cancer immunology, immunotherapy : CIIFree full text
  152. HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer.2021Cancer scienceFree full text
  153. Sodium/glucose cotransporter 1-dependent metabolic alterations induce tamoxifen resistance in breast cancer by promoting macrophage M2 polarization.2021Cell death & diseaseFree full text
  154. LncRNA TINCR favors tumorigenesis via STAT3-TINCR-EGFR-feedback loop by recruiting DNMT1 and acting as a competing endogenous RNA in human breast cancer.2021Cell death & diseaseFree full text
  155. Single-Cell Proteomic Profiling Identifies Nanoparticle Enhanced Therapy for Triple Negative Breast Cancer Stem Cells.2021CellsFree full text
  156. Dynamic biomarkers indicate the immunological benefits provided by Ganoderma spore powder in post-operative breast and lung cancer patients.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoRCT
  157. Nomogram Predicting the Risk of Locoregional Recurrence After Mastectomy for Invasive Micropapillary Carcinoma of the Breast.2021Clinical breast cancer
  158. NEFM DNA methylation correlates with immune infiltration and survival in breast cancer.2021Clinical epigeneticsFree full text
  159. Caspase-3-mediated GSDME induced Pyroptosis in breast cancer cells through the ROS/JNK signalling pathway.2021Journal of cellular and molecular medicineFree full text
  160. Laser-triggered combination therapy by iron sulfide-doxorubicin@functionalized nanozymes for breast cancer therapy.2021Journal of nanobiotechnologyFree full text
  161. N6-Methyladenosine Regulators Are Involved in the Progression of and Have Clinical Impact on Breast Cancer.2021Medical science monitor : international medical journal of experimental and clinical researchFree full text
  162. FOXO3A-induced LINC00926 suppresses breast tumor growth and metastasis through inhibition of PGK1-mediated Warburg effect.2021Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  163. GLUT1 participates in tamoxifen resistance in breast cancer cells through autophagy regulation.2021Naunyn-Schmiedeberg's archives of pharmacology
  164. Tumor-associated macrophages increase COX-2 expression promoting endocrine resistance in breast cancer via the PI3K/Akt/mTOR pathway.2021Neoplasma
  165. Correlations of social isolation and anxiety and depression symptoms among patients with breast cancer of Heilongjiang province in China: The mediating role of social support.2021Nursing openFree full text
  166. Application of conventional ultrasonography combined with contrast-enhanced ultrasonography in the axillary lymph nodes and evaluation of the efficacy of neoadjuvant chemotherapy in breast cancer patients.2021The British journal of radiologyFree full text
  167. CST6 protein and peptides inhibit breast cancer bone metastasis by suppressing CTSB activity and osteoclastogenesis.2021TheranosticsFree full text
  168. AKT inhibitor AZD5363 suppresses stemness and promotes anti-cancer activity of 3,3'-diindolylmethane in human breast cancer cells.2021Toxicology and applied pharmacology
Chinese-language papers (not in the count)2
  1. [Effectiveness of sequential method pure single-port lumpectomy-breast conserving surgery for early-stage breast cancer in different quadrants].2024Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgeryFree full text
  2. [Tyro3 and CDK9 as biomarkers for drug resistance to breast cancer anti-PD-1 therapies].2023Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status116
  1. Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast CancerNot yet recruitingNCT07752550Lead (inferred)Phase 2Start 2026-07
  2. Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and EfficacyActive, not recruitingNCT07471815Lead (inferred)Phase 2Start 2026-03
  3. Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast CancerActive, not recruitingNCT06599216Lead (inferred)Phase 2Start 2024-10
  4. Effectiveness and Toxicity of Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin as Second-line Treatment in Metastatic Breast CancerStatus unknownNCT01483300Lead (inferred)Phase 2Start 2011-11
  5. A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast CancerRecruitingNCT07347600Study siteStart 2026-01
  6. Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)RecruitingNCT07383818Study sitePhase 2Start 2026-02
  7. Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.Not yet recruitingNCT07487519Study sitePhase 2Start 2026-04
  8. A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)RecruitingNCT07876557Study sitePhase 2Start 2026-10
  9. A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.Not yet recruitingNCT07623642Study sitePhase 2Start 2026-06
  10. A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast CancerNot yet recruitingNCT07560124Study sitePhase 1/Phase 2Start 2026-06
  11. A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast CancerRecruitingNCT07281976Study sitePhase 1/Phase 2Start 2026-01
  12. BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseRecruitingNCT07492641Study sitePhase 3Start 2026-05
  13. A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer PatientsRecruitingNCT06679036Study sitePhase 1/Phase 2Start 2025-01
  14. A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBCEnrolling by invitationNCT07376629Study sitePhase 2Start 2025-08
  15. A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerRecruitingNCT07043725Study sitePhase 3Start 2025-09
  16. TQB2930 Injection for the Treatment of HER2-positive Advanced Breast CancerRecruitingNCT07047365Study sitePhase 3Start 2025-07
  17. Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastasesRecruitingNCT07469267Study siteN/AStart 2025-10
  18. Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)RecruitingNCT06977893Study sitePhase 3Start 2025-03
  19. A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerRecruitingNCT06891833Study sitePhase 2/Phase 3Start 2025-06
  20. A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)RecruitingNCT07174336Study sitePhase 3Start 2025-12
  21. JS207 Combination Therapy in Triple-negative Breast CancerRecruitingNCT07045311Study sitePhase 2Start 2025-09
  22. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.RecruitingNCT07062965Study sitePhase 3Start 2025-08
  23. A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsRecruitingNCT07169994Study sitePhase 1/Phase 2Start 2025-09
  24. An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid TumorsRecruitingNCT07222267Study sitePhase 1Start 2025-12
  25. A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerRecruitingNCT07673029Study sitePhase 3Start 2025-01
  26. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerRecruitingNCT06790693Study sitePhase 3Start 2025-04
  27. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingNCT06966700Study sitePhase 3Start 2025-06
  28. A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)RecruitingNCT06210776Study siteStart 2024-01
  29. Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)RecruitingNCT06682195Study sitePhase 2Start 2024-10
  30. A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid TumorsRecruitingNCT06503783Study sitePhase 1Start 2024-08
  31. A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011Not yet recruitingNCT06354114Study sitePhase 2Start 2024-04
  32. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingNCT06324357Study sitePhase 1/Phase 2Start 2024-06
  33. The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast CancerRecruitingNCT06452706Study sitePhase 2Start 2024-11
  34. Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)RecruitingNCT06611813Study sitePhase 2Start 2024-06
  35. A Study of YL202 in Selected Patients With Advanced Solid TumorsRecruitingNCT06107686Study sitePhase 2Start 2023-12
  36. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsRecruitingNCT06120283Study sitePhase 1Start 2023-12
  37. Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.RecruitingNCT05872347Study sitePhase 2Start 2023-09
  38. Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast CancerRecruitingNCT05860465Study sitePhase 2/Phase 3Start 2023-09
  39. JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer SubjectsRecruitingNCT06079983Study sitePhase 3Start 2023-12
  40. A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast CancerRecruitingNCT06954961Study sitePhase 3Start 2022-09
  41. Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast CancerRecruitingNCT04136782Study sitePhase 4Start 2021-07
  42. Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine TherapyRecruitingNCT04476485Study siteStart 2021-07
  43. Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerTerminatedNCT06851442Study sitePhase 1/Phase 2Start 2025-05
  44. Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseActive, not recruitingNCT06760637Study sitePhase 3Start 2025-01
  45. Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast CancerActive, not recruitingNCT06702618Study sitePhase 2Start 2025-02
  46. A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)Active, not recruitingNCT06680921Study sitePhase 3Start 2024-11
  47. A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsActive, not recruitingNCT06257264Study sitePhase 1Start 2024-03
  48. PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBCActive, not recruitingNCT06419621Study sitePhase 3Start 2024-06
  49. A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerActive, not recruitingNCT06198751Study sitePhase 2Start 2024-02
  50. A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast CancerCompletedNCT05945927Study siteStart 2023-09
  51. A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast CancerActive, not recruitingNCT05654623Study sitePhase 3Start 2023-03
  52. Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine TherapyActive, not recruitingNCT05840211Study sitePhase 3Start 2023-05
  53. A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast CancerCompletedNCT06115902Study sitePhase 1Start 2023-11
  54. A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Active, not recruitingNCT06065748Study sitePhase 3Start 2023-12
  55. FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast CancerStatus unknownNCT05755048Study sitePhase 3Start 2023-03
  56. A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast CancerActive, not recruitingNCT05257395Study sitePhase 3Start 2022-03
  57. Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BCStatus unknownNCT05400993Study sitePhase 2Start 2022-05
  58. Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)Active, not recruitingNCT05382364Study sitePhase 1Start 2022-06
  59. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903CompletedNCT06846099Study sitePhase 1Start 2022-12
  60. Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) StudiesActive, not recruitingNCT05226871Study sitePhase 2Start 2022-07
  61. A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast CancerActive, not recruitingNCT05346224Study sitePhase 3Start 2022-04
  62. Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerActive, not recruitingNCT05382299Study sitePhase 3Start 2022-07
  63. A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast CancerStatus unknownNCT05433480Study sitePhase 3Start 2022-05
  64. Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast CancerActive, not recruitingNCT04851613Study sitePhase 3Start 2022-02
  65. A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative TherapyActive, not recruitingNCT04873362Study sitePhase 3Start 2021-05
  66. A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Active, not recruitingNCT04961996Study sitePhase 3Start 2021-08
  67. A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast CancerTerminatedNCT04927481Study sitePhase 2Start 2021-06
  68. A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)TerminatedNCT04740918Study sitePhase 3Start 2021-06
  69. A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast CancerTerminatedNCT05103826Study sitePhase 1Start 2021-10
  70. A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast CancerCompletedNCT04796623Study sitePhase 2Start 2021-02
  71. A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerActive, not recruitingNCT04975308Study sitePhase 3Start 2021-10
  72. Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid TumorsStatus unknownNCT05145907Study sitePhase 2Start 2021-12
  73. Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .Status unknownNCT04234620Study siteStart 2020-02
  74. A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)Active, not recruitingNCT04546009Study sitePhase 3Start 2020-10
  75. A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)Active, not recruitingNCT04622319Study sitePhase 3Start 2020-12
  76. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  77. A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast CancerCompletedNCT04024462Study sitePhase 3Start 2020-02
  78. A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerActive, not recruitingNCT04191499Study sitePhase 2/Phase 3Start 2020-01
  79. A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast CancerCompletedNCT03872791Study sitePhase 1/Phase 2Start 2019-05
  80. Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast CancerStatus unknownNCT03926091Study sitePhase 3Start 2019-04
  81. Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast CancerStatus unknownNCT04165993Study sitePhase 2Start 2019-12
  82. Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBCActive, not recruitingNCT03562637Study sitePhase 3Start 2018-12
  83. A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast CancerCompletedNCT03371017Study sitePhase 3Start 2018-01
  84. The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast CancerStatus unknownNCT04185649Study sitePhase 3Start 2018-07
  85. A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver MetastasesStatus unknownNCT03500380Study sitePhase 2/Phase 3Start 2018-04
  86. Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)Active, not recruitingNCT03725059Study sitePhase 3Start 2018-12
  87. A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast CancerTerminatedNCT03498716Study sitePhase 3Start 2018-08
  88. Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in ChinaCompletedNCT03575065Study sitePhase 2Start 2018-06
  89. DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]CompletedNCT03529110Study sitePhase 3Start 2018-08
  90. Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic TreatmentCompletedNCT04085276Study sitePhase 3Start 2018-12
  91. A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.Status unknownNCT04385563Study sitePhase 3Start 2018-11
  92. Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]CompletedNCT03734029Study sitePhase 3Start 2018-12
  93. Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast CancerStatus unknownNCT03692689Study sitePhase 2Start 2018-07
  94. A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)CompletedNCT03125902Study sitePhase 3Start 2017-08
  95. Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line TherapyActive, not recruitingNCT03315364Study sitePhase 2/Phase 3Start 2017-12
  96. Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast CancerActive, not recruitingNCT03155997Study sitePhase 3Start 2017-07
  97. Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast CancerCompletedNCT03084939Study sitePhase 3Start 2017-04
  98. Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast CancerStatus unknownNCT03351062Study sitePhase 3Start 2017-11
  99. Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast CancerCompletedNCT03084237Study sitePhase 3Start 2016-11
  100. A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced BreastStatus unknownNCT03047889Study siteStart 2016-04
  101. A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerCompletedNCT02896855Study sitePhase 3Start 2016-09
  102. Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast CancerActive, not recruitingNCT02455141Study sitePhase 3Start 2016-03
  103. Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + DocetaxelCompletedNCT02586025Study sitePhase 3Start 2016-03
  104. Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young WomenStatus unknownNCT02914158Study sitePhase 3Start 2016-03
  105. Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)CompletedNCT02568267Study sitePhase 2Start 2015-11
  106. Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast CancerCompletedNCT02499146Study sitePhase 1Start 2015-09
  107. A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]CompletedNCT02297438Study sitePhase 3Start 2015-03
  108. Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast CancerCompletedNCT02482753Study sitePhase 3Start 2015-07
  109. Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast CancerCompletedNCT02253459Study sitePhase 3Start 2014-08
  110. Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer PatientsStatus unknownNCT01939054Study sitePhase 2Start 2013-09
  111. A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)CompletedNCT01772472Study sitePhase 3Start 2013-04
  112. A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based TreatmentCompletedNCT01702571Study sitePhase 3Start 2012-11
  113. Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast CancerStatus unknownNCT01492556Study sitePhase 2Start 2011-12
  114. A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerCompletedNCT01358877Study sitePhase 3Start 2011-11
  115. Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In ChinaCompletedNCT01176916Study sitePhase 4Start 2011-02
  116. Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast CancerCompletedNCT02613026Study sitePhase 3Start 2009-07

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 14 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.2%.

Papers led
14
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 4420232024: 2220242025: 442025

4 hospitals in Harbin for glioma187 hospitals in China for glioma

No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryRadiation oncologyGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led14
  1. Targeting BACH1 by HPPE inhibits the Wnt/β-catenin pathway and malignant phenotype in glioblastoma cells.2025Apoptosis : an international journal on programmed cell death
  2. Role of SIX5-mediated EXO1 overexpression in driving glioblastoma progression: Insights into tumor cell migration and angiogenesis.2025Brain research
  3. Multi-omics-guided characterization of neoantigens improves patient stratification and potentiates combinatorial immunotherapy in glioma.2025Cell reports
  4. Correlation of miR-3188 with patient prognosis and mechanistic inhibition of glioma proliferation, invasion, and migration by targeting MAPK1.2025Folia neuropathologica
  5. Intraoperative radiotherapy in recurrent IDH-wildtype glioblastoma with gross total resection: A single-center retrospective study.2024Clinical neurology and neurosurgery
  6. The Relationship Between the Molecular Phenotypes of Brain Gliomas and the Imaging Features and Sensitivity of Radiotherapy and Chemotherapy.2024Clinical oncology (Royal College of Radiologists (Great Britain))
  7. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.2023Functional & integrative genomics
  8. Reply to: Comments on "New insights into glioma frequency maps: From genetic and transcriptomic correlate to survival prediction".2023International journal of cancer
  9. New insights into glioma frequency maps: From genetic and transcriptomic correlate to survival prediction.2023International journal of cancerFree full text
  10. RPL34-Divergent Transcript, a Novel Long NonCoding Ribonucleic Acid, Promotes Migration by Activating Epithelial-Mesenchymal Transition in Glioma.2023World neurosurgery
  11. Circular RNA circBFAR promotes glioblastoma progression by regulating a miR-548b/FoxM1 axis.2022FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  12. GBAS Regulates the Proliferation and Metastasis of Ovarian Cancer Cells by Combining with eEF1A1.2022The oncologistFree full text
  13. Circular RNA circHECTD1 facilitates glioma progression by regulating the miR-296-3p/SLC10A7 axis.2021Journal of cellular physiology
  14. circFLNA promotes glioblastoma proliferation and invasion by negatively regulating miR‑199‑3p expression.2021Molecular medicine reportsFree full text

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Harbin for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

5 hospitals in Harbin for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 6 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.4%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 0020232024: 1120242025: 112025

3 hospitals in Harbin for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-06
    Posted
    Registry
    NCT06574568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Jinan, Taiyuan, Zhengzhou

  3. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Posted
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskCAR-T & cell therapyDrug combinations

Over half of these papers are lab or animal studies.

Papers it led6
  1. HNRNPA2B1 Promotes the Progression of Multiple Myeloma via Endoplasmic Reticulum Stress and Autophagy Mediated by CK2 Kinase.2025Journal of proteome research
  2. Prognostic marker CD27 and its micro-environmental in multiple myeloma.2024BMC cancerFree full text
  3. Non-invasive discrimination of multiple myeloma using label-free serum surface-enhanced Raman scattering spectroscopy in combination with multivariate analysis.2022Analytica chimica acta
  4. IP-10 enhances the amplification capacity and antitumor activity of CAR-T cells in vitro and could influence positive outcomes in MM patients treated with CAR-T cell therapy.2022International immunopharmacology
  5. HNRNPA2B1-mediated m6A modification of TLR4 mRNA promotes progression of multiple myeloma.2022Journal of translational medicineFree full text
  6. Proteomics-Based Approach Reveals the Involvement of SERPINB9 in Recurrent and Relapsed Multiple Myeloma.2021Journal of proteome research
All its trials on ClinicalTrials.gov, any status8
  1. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  2. A Study of YKST02 in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06574568Study sitePhase 1Start 2024-06
  3. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  4. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Study sitePhase 3Start 2023-03
  5. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.CompletedNCT05228470Study sitePhase 2Start 2021-12
  6. A Study of Ninlaro in Real World Clinical Practice in ChinaCompletedNCT04328662Study siteStart 2020-05
  7. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  8. Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid TherapyCompletedNCT02609828Study sitePhase 3Start 2015-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 26 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
26
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
12
led by another institution
Papers led per year
2021: 4420212022: 2220222023: 5520232024: 8820242025: 772025

3 hospitals in Harbin for lymphoma199 hospitals in China for lymphoma

Open trials with this hospital 12

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07409428

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
    Phase
    Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06742996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Wenzhou, Wuhan, Xuzhou, Zhengzhou

  3. Recruiting
    Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06829771

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Lanzhou, Luzhou, Quanzhou, Shanghai, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Zhengzhou

  4. Recruiting
    Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06854445

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangsha, Dalian, Hangzhou, Harbin, Jinan, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Shijiazhuang, Suzhou, Taiyuan, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou

  5. Recruiting
    A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06943872

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hohhot, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Wuxi, Xiamen, Yangzhou

  6. Recruiting
    An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07200375

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan, Nanchang, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai, Zhengzhou

  7. Recruiting
    A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06566586

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Guangzhou, Harbin, Hohhot, Lanzhou, Luzhou, Nanchang, Nanning, Shanghai, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  8. Recruiting
    A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT07234162

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  9. Recruiting
    First in Human, Dose Escalation Study of AN4005
    Phase
    Phase 1
    Started
    2021-09
    Posted
    Registry
    NCT04999384

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Harbin, Wuhan

  10. Not yet recruiting
    Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
    Phase
    Phase 2/Phase 3
    Started
    2026-09
    Posted
    Registry
    NCT07712588

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangsha, Chongqing, Harbin, Shanghai

  11. Not yet recruiting
    Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07896590

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

  12. Not yet recruiting
    Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07206264

    Age 60 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 3 listed hospitals as study sitesFuzhou, Harbin, Jinan, Tianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyRadiation oncologyRadiology / nuclear medicine
Papers it led26
  1. Feasibility analysis of metabolic parameters based on baseline 18F-FDG PET/CT to predict heterogeneity and recurrence of diffuse large B-cell lymphoma.2025Annals of hematologyFree full text
  2. Genomic mutation profile and metabolic alterations in diffuse large B-cell lymphoma with abdominal bulky mass.2025Annals of hematologyFree full text
  3. The association between NADPH oxidase (NOX) polymorphisms with immunohistochemistry and survival in diffuse large B cell lymphoma patients.2025Annals of hematology
  4. BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies.2025Blood reviews
  5. Upregulated miR-29a-3p Prevent Malignant Features of Lymphoma Cells by Targeting MCL1.2025Hematological oncology
  6. Effect of metabolic syndrome on prognosis in patients with peripheral T-cell lymphoma.2025Hematology (Amsterdam, Netherlands)
  7. Factors affecting refractoriness or recurrence in diffuse large B-cell lymphoma: development and validation of a novel predictive nomogram.2025Hematology (Amsterdam, Netherlands)
  8. Fat mass and obesity-associated protein (FTO)-induced upregulation of flotillin-2 (FLOT2) contributes to cancer aggressiveness in diffuse large B-cell lymphoma (DLBCL) via activating the PI3K/Akt/mTOR signal pathway.2024Archives of biochemistry and biophysics
  9. Pyroptotic macrophages promote proliferation and chemotherapy resistance of peripheral T-cell lymphoma via TLR4 signaling pathway.2024Cancer scienceFree full text
  10. A retrospective analysis of the clinicopathological features and prognostic value of MAPK12 protein expression in diffuse large B-cell lymphoma.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoFree full text
  11. The effect of metabolic syndrome on prognosis of diffuse large B-cell lymphoma.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of MexicoFree full text
  12. High PPP4C expression predicts poor prognosis in diffuse large B-cell lymphoma.2024Clinical and experimental medicineFree full text
  13. Rare Metastatic Embryonal Carcinoma Resembling Lymphoma: A Case Report.2024Current medical imaging
  14. Analysis and Investigation of Bioinformatics and Epigenetics Reveal the Underlying Mechanisms by which FLOT2 Modulates the Progression of Diffuse Large B-cell Lymphoma.2024Discovery medicine
  15. Joint Analysis of CCAAT/Enhancer-Binding Protein Beta and Interleukin 1 Beta in the Treatment and Prognosis of Diffuse Large B-Cell Lymphoma.2024Frontiers in bioscience (Landmark edition)
  16. Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.2023Autoimmunity
  17. Development and validation of a [18F]FDG PET/CT-based radiomics nomogram to predict the prognostic risk of pretreatment diffuse large B cell lymphoma patients.2023European radiologyFree full text
  18. Identification and validation of hub genes in CD5-positive diffuse large B-cell lymphoma.2023Experimental biology and medicine (Maywood, N.J.)Free full text
  19. A new nomogram for assessing complete response (CR) in gastric diffuse large B-cell lymphoma (DLBCL) patients after chemotherapy.2023Journal of cancer research and clinical oncologyFree full text
  20. MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway.2023PeerJFree full text
  21. A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma.2022Leukemia & lymphoma
  22. Diagnosis and staging of diffuse large B-cell lymphoma using label-free surface-enhanced Raman spectroscopy.2022Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  23. High dose and hepatobiliary dysfunction are associated with hand-foot syndrome in patients with lymphoma using pegylated liposomal doxorubicin: a retrospective study.2021BMC pharmacology & toxicologyFree full text
  24. Clinicopathologic significance of MYD88 L265P mutation and expression of TLR4 and P-STAT3 in primary central nervous system diffuse large B-cell lymphomas.2021Brain tumor pathology
  25. Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy.2021Current oncology (Toronto, Ont.)Free full text
  26. Helicobacter pylori infection disturbs the tumor immune microenvironment and is associated with a discrepant prognosis in gastric de novo diffuse large B-cell lymphoma.2021Journal for immunotherapy of cancerFree full text
All its trials on ClinicalTrials.gov, any status44
  1. A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLRecruitingNCT07409428Study sitePhase 3Start 2026-03
  2. Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone LymphomaNot yet recruitingNCT07896590Study sitePhase 3Start 2026-10
  3. Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)Not yet recruitingNCT07712588Study sitePhase 2/Phase 3Start 2026-09
  4. A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)RecruitingNCT06943872Study sitePhase 3Start 2025-06
  5. Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT AssessmentNot yet recruitingNCT07206264Study sitePhase 2Start 2025-10
  6. An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell LymphomaRecruitingNCT07200375Study siteStart 2025-09
  7. Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell LymphomaRecruitingNCT06829771Study sitePhase 1/Phase 2Start 2025-04
  8. A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)RecruitingNCT06742996Study sitePhase 3Start 2025-03
  9. Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell LymphomaRecruitingNCT06854445Study sitePhase 2Start 2025-03
  10. A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell LymphomaRecruitingNCT06566586Study sitePhase 2Start 2024-11
  11. A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)RecruitingNCT07234162Study sitePhase 3Start 2024-05
  12. First in Human, Dose Escalation Study of AN4005RecruitingNCT04999384Study sitePhase 1Start 2021-09
  13. Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood CancersActive, not recruitingNCT07162181Study sitePhase 2Start 2025-08
  14. A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) InhibitorsActive, not recruitingNCT06970743Study sitePhase 3Start 2025-05
  15. Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCLCompletedNCT06601504Study sitePhase 2Start 2024-11
  16. A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT06508658Study sitePhase 3Start 2024-08
  17. An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell LymphomaActive, not recruitingNCT06047080Study sitePhase 3Start 2023-09
  18. A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Active, not recruitingNCT05578976Study sitePhase 3Start 2023-02
  19. HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT05190068Study sitePhase 1Start 2022-01
  20. A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaActive, not recruitingNCT05100862Study sitePhase 3Start 2022-03
  21. A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT04657302Study sitePhase 1Start 2021-01
  22. A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT04408638Study sitePhase 3Start 2021-02
  23. A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)CompletedNCT04849416Study sitePhase 2Start 2021-05
  24. A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT04660799Study sitePhase 2Start 2021-02
  25. Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor ZanubrutinibCompletedNCT05068440Study sitePhase 2Start 2021-08
  26. A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular LymphomaActive, not recruitingNCT04712097Study sitePhase 3Start 2021-10
  27. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT03992339Study sitePhase 2Start 2020-04
  28. A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).TerminatedNCT04236141Study sitePhase 3Start 2020-07
  29. Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin LymphomaTerminatedNCT04486391Study sitePhase 3Start 2020-12
  30. Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell LymphomaTerminatedNCT04002622Study sitePhase 2Start 2019-08
  31. A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell TransplantationActive, not recruitingNCT04002297Study sitePhase 3Start 2019-08
  32. BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)CompletedNCT03520920Study sitePhase 2Start 2018-01
  33. Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™CompletedNCT03263026Study sitePhase 3Start 2018-03
  34. A Study of CS1003 in Subjects With Advanced Solid Tumors or LymphomasCompletedNCT03809767Study sitePhase 1Start 2018-10
  35. Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell NeoplasmsCompletedNCT03493451Study sitePhase 2Start 2018-04
  36. A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular LymphomaCompletedNCT03332017Study sitePhase 2Start 2017-11
  37. Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/LymphomaStatus unknownNCT03374007Study sitePhase 1Start 2017-10
  38. Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell LymphomaCompletedNCT03145064Study sitePhase 2Start 2017-06
  39. A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02838420Study sitePhase 3Start 2016-08
  40. A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma PatientsCompletedNCT02945215Study sitePhase 1Start 2016-12
  41. Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell MalignanciesCompletedNCT02795182Study sitePhase 1Start 2016-06
  42. Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)CompletedNCT02568267Study sitePhase 2Start 2015-11
  43. A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)TerminatedNCT01287741Study sitePhase 3Start 2011-07
  44. A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)CompletedNCT01332968Study sitePhase 3Start 2011-07

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led no English-language PubMed papers on Fanconi anaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Harbin for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Harbin for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

哈尔滨医科大学附属肿瘤医院

Harbin Medical University Cancer Hospital

哈尔滨

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Harbin medical university cancer hospital; Third Affiliated Hospital of Harbin Medical University; 哈尔滨医科大学第三临床医学院

Suggest a correctionDownload the data